



Arbitration CAS 2015/A/4008 International Association of Athletics Federations (IAAF) v. All Russia Athletics Federation (ARAF), Olga Kaniskina & Russian Anti-Doping Agency (RUSADA), award of 25 April 2016 (operative award of 24 March 2016)

Panel: Prof. Luigi Fumagalli (Italy), President; Mr Romano Subiotto QC (United Kingdom); Mr Mika Palmgren (Finland)

Athletics (race walking)

Doping (Athlete's Biological Passport, ABP)

Athlete Biological Passport as evidence

*Principle of *lex mitior**

Concept of fairness

Principle of proportionality

1. An athlete who, based on his Athlete Biological Passport (ABP), is found guilty of an anti-doping rule violation and criticises the reliability of the ABP but does not challenge the respective decision accepts the conclusion that his ABP constituted sufficient evidence to ground the conclusion that he committed an anti-doping rule violation. Conversely, the criticism as to the reliability of the ABP can be understood as aiming to show that insufficient evidence has been submitted to prove that some of the samples included in the ABP of the athlete are abnormal, and therefore to allow the conclusion, from the athlete's perspective, that they should not be taken into account when determining whether the results achieved in the period surrounding those disputed samples have to be disqualified. In the same way, the athlete may invoke any alleged unreliability of the ABP method as a factor to be taken into account when assessing, in general terms, the "fairness" of the disqualification (or of the non-disqualification) of his results.
2. When applying the *lex mitior* principle in case of anti-doping rule violations, either the set of rules applicable at the time when the anti-doping rule violation was committed or otherwise the rules applicable at the time the decision is adopted are to be determined as the applicable set of rules most favourable to the accused, without picking individual provisions from each. The hearing body cannot undertake a rule-by-rule comparison of the two systems, picking the most favourable rule of each system.
3. The concept of "fairness" is a broad one, covering a number of elements that the deciding body can take into account in its decision not to disqualify some results. In the past CAS panels took into account a number of factors, such as the nature and severity of the infringement, the length of time between the anti-doping rule violation, the result to be disqualified and the disciplinary decision, the presence of negative tests between the anti-doping rule violation and the competition at which the result to be disqualified was achieved, and the effect of the infringement on the result at stake. It is

not a single element that is decisive alone: an overall evaluation of them is necessary.

4. The principle of proportionality implies that there must be a reasonable balance between the kind of misconduct and the sanction, and in particular that (i) the measure taken by the governing body can achieve the envisaged goal, (ii) the measure taken by the governing body is necessary to reach the envisaged goal, and (iii) the constraints on the affected person resulting from the measure are justified by the overall interest of achieving the envisaged goal. In other words, to be proportionate, a measure must not exceed what is reasonably required in the search for a legitimate objective.

I. BACKGROUND

1.1 The Parties

1. The International Association of Athletics Federations (“IAAF” or the “Appellant”) is the international federation for the sport of athletics. IAAF is an association under the laws of Monaco and has its headquarters in Monte Carlo, Monaco.
2. The All Russia Athletics Federation (“ARAF” or the “First Respondent”) is the national governing body for the sport of athletics in the Russian Federation and the Member Federation of IAAF for the Russian Federation.
3. Ms Olga Kaniskina (the “Athlete” or the “Second Respondent”) is an international-level athlete of Russian nationality specialising in the 20 kilometres race walk event, who has competed at an elite international level for a number of years with considerable success.
4. The Russian Anti-Doping Agency (“RUSADA” or the “Third Respondent”) is the national anti-doping agency established for the Russian Federation.
5. ARAF, the Athlete and RUSADA are hereinafter jointly referred to as the “Respondents”.

1.2 The Dispute between the Parties

6. The object of the dispute between the parties is a portion of a decision issued by a disciplinary committee of RUSADA in an anti-doping case brought against the Athlete, based on the irregularities observed between August 2009 and August 2012 in the athlete’s biological passport (the “ABP”) concerning the Athlete. IAAF started the present arbitration claiming that the applicable anti-doping rules adopted by IAAF (the “IAAF ADR”) to implement the provisions of the World Anti-Doping Code (the “WADC”) had not been correctly applied on a specific point (disqualification of results).
7. The circumstances stated below summarize the main relevant facts concerning the dispute, as

submitted by the parties in their written pleadings or in the evidence offered during the course of the proceedings. Additional facts may be set out, where relevant, in connection with the following legal discussion.

8. A preliminary point of explanation is however necessary to clarify the factual background of the dispute. As mentioned, it follows the application of the ABP model to the Athlete, and some discussions took place in this arbitration about the ABP and its evidentiary value to establish an anti-doping rule violation, and more specifically the use of a prohibited substance or of a prohibited method. As submitted by IAAF, unlike direct detection methods, the ABP focuses on the effect of prohibited substances or methods on the body, rather than on their detection. For such purposes, the ABP was developed as an individual, electronic record for each athlete, in which the results of all doping tests over a period of time are collated. The ABP involves regular monitoring of biological markers on a longitudinal basis to facilitate the indirect detection of prohibited substances and methods. The list of relevant markers for a specific class of substance (*e.g.*, substances enhancing oxygen transfer such as recombinant EPO) are identified and monitored on a regular basis for a given athlete, in order to establish an effective longitudinal monitoring program. The collection and monitoring of values corresponding to these identified markers constitutes an individual longitudinal profile. Each collected sample is analysed following the appropriate analytical protocol and the biological results are incorporated into the Anti-Doping Administration and Management System (ADAMS), which is a web-based database management tool for data entry, storage, sharing, and reporting designed to assist stakeholders and the World Anti-Doping Agency (“WADA”) in their anti-doping operations. The statistical model developed for the ABP program is then applied to the results of analyses to determine an abnormal profile score. More specifically, once the new biological data are entered in ADAMS, a notification is sent to the Athlete Passport Management Unit, which updates the Athlete’s Passport and applies the ABP software, *i.e.* the Adaptive Model. The Adaptive Model is a mathematical model that was designed to identify unusual longitudinal results from athletes. The model calculates the probability of a longitudinal profile of marker values assuming that the athlete has a normal physiological condition. The Athlete Passport Management Unit proceeds with the mandatory steps outlined in the rules, which includes liaising with an expert panel established by the IAAF, if the athlete’s haemoglobin (HGB) and/or OFF-hr-Score (OFFS) values exceed the 99.9 percentile of the expected ranges returned by the Adaptive Model. The statistical result for the athlete does not in itself justify a conclusion that an anti-doping rule violation has occurred, but calls for an explanation by the athlete.
9. In 2009, IAAF started its ABP program. The Athlete was included by the IAAF in its ABP program and subjected to twelve in- and out-of-competition blood sample collections between August 2009 and August 2012. The analyses gave the following results¹:

¹ Such results are taken from the IAAF appeal brief in this arbitration, and are in themselves undisputed.

	COLLECTION DATE	RET [%]	HGB	OFF-SCORE
1	15.08.2009	0.21	13.7	109.50
2	16.08.2009	0.15	15.0	126.80
3	27.07.2010	0.14	14.7	124.55
4	01.03.2011	0.32	14.1	107.10
5	22.05.2011	0.12	14.2	121.20
6	16.07.2011	0.94	14.2	83.80
7	30.08.2011	0.16	15.9	135.00
8	08.10.2011	2.93	15.0	47.30
9	07.01.2012	1.31	14.1	72.30
10	13.04.2012	2.32	14.4	52.60
11	11.05.2012	0.86	14.7	91.40
12	10.08.2012	0.57	14.1	95.70

10. The biomarker values from the samples collected from the Athlete were considered to be highly abnormal. As a consequence, the resulting Athlete's profile was sent to three independent experts, who unanimously concluded, in their initial review (the "Initial Review"), that this profile was "highly unlikely" to be "the result of a normal physiological or pathological condition, and may be the result of the use of a prohibited substance or prohibited method"². In particular:

i. Professor Yorck Olaf Schumacher³ in an opinion dated 26 June 2012 (following a preceding one of 18 January 2012) observed that:

"As recommended in my initial review dated January 18th, 2012, three additional samples have now been obtained from this female athlete (samples 9-11). In addition, another sample dated March 1st, 2011 was added to the profile (note that the sample numbers have therefore now changed and do not match the sample numbers of the initial expertise). I received the documentation packages, anonymised whereabouts, competition information and the results of further blood tests from the IAAF for evaluation.

The key concern in my initial review was the sometimes prominent anisocytosis illustrated by elevated RDW SD. One of the possible causes that remained to be excluded was an underlying red cell disease causing this pattern. The more recent samples (new sample numbers 9, 10, 11) show normal red cell indices and an RDW at the upper end of the normal range. Beside a slightly elevated white cell count (neutrophils with relative lymphopenia) in sample 10, no other indications for pathologies are found. The data therefore show that it is unlikely that any underlying red cell pathology has caused the variations seen in the profile.

In the profile, Reticulocyte values are very high and very low at times, Haemoglobin relatively stable throughout the observation period with the highest values observed in samples 2 and 7. Coincidentally, these samples also show very low reticulocytes and the highest OFF score values of the profile (126 and 135). The samples were taken in August 2009 and August 2011 at the IAAF World championships

² It is to be noted that the Initial Review was conducted on the first eleven samples. It therefore did not take into account sample 12.

³ Professor of internal medicine and sports medicine at the University of Freiburg, Germany.

of the respective years, thus making a manipulation scenario with increased red cell mass and subsequently suppressed erythropoiesis for these competitions highly likely. This assumption is supported by the results of the blood tests from the IAAF blood testing program that are not included in the ABP: The athlete shows very suspicious values with high OFF scores matching important competitions (Beijing 2008 Olympics).

I therefore conclude that absent a satisfactory explanation from the athlete, it is highly unlikely that the athlete's longitudinal profile is the result of a normal physiological or pathological condition or is caused by analytical alterations to the sample. It is, in contrast, highly likely that it is the result of the use of a prohibited substance or a prohibited method ...”;

ii. Professor Giuseppe d’Onofrio⁴ expressed on 25 June 2012 the following opinion:

“The profile is composed of eleven valid test performed between August 2009 and May 2012.

The most significant finding in this profile is the important increase of the OFF score close to important competitions. This is mainly due to very low reticulocyte percentages. Reticulocytopenia is never physiological. It is the consequence of suppressed red cell production that can be due to:

- 1. a blood/ marrow disease, which impairs red cell formation;*
- 2. cytotoxic therapy, like those used to treat cancer;*
- 3. some uncommon viral infections;*
- 4. inhibition of erythropoiesis due to suspension of EPO or other ESA in blood doping.*

In the first three conditions mentioned above, anemia is the consequence of insufficient production and release of newly formed reticulocytes. A very high OFF score, with high hemoglobin and low reticulocytes, is truly unusual in normal physiology, but also in human pathology; on the contrary, it is typical of the fourth condition mentioned above

Hematologic assessment of the most abnormal sample results

Sample 1 was collected shortly before the Berlin 2009 World Championship: hemoglobin is not high, but reticulocytes are 0.2% and the OFF score 109.5.

Sample 2, from the following day, shows features of post-competition collection (neutrophilia, disappearance of eosinophils); increase in hemoglobin could partially be caused by hemoconcentration, but the further decrease in reticulocytes has nothing to do with physical strain. Off score is increased to 126.8.

Sample 3 was collected in Barcelona, after a stay in altitude, and shortly before the 2010 European Championship. Hemoglobin is in the high female range, and again reticulocytes are extremely low (0.14%), with an OFF score of 124.6. This is an even clearer picture of what cheating athletes who use ESA usually do at the time of top competitions.

Sample 5, collected 45 days after the Rio Major race and three months before the Daegu 2011 World Championship, shows a severe erythropoietic inhibition, which has no apparent correlation with competitions, but is very likely caused by a previous ESA treatment. Reticulocytes are low (0.12%), OFF score is high (121.2), the fraction of immature reticulocytes (IRF) is zero.

⁴ Professor of clinical pathology and immunohematology at the Catholic University of the Sacred Heart in Rome, Italy.

Sample 6, less than two months later, still out of competition but closer to Daegu, shows, on the contrary, clear signs of ESA stimulation. Reticulocytes are in the normal range, but a very high IRF demonstrates that there are many very young reticulocytes in the blood, such as those produced when erythropoiesis is strongly stimulated. Administration of Epo or withdrawal of blood for autologous transfusion are possible causes. This sample shows additional abnormalities in the high MCV and RDW, which indicate red cell anisocytosis. The QC in the laboratory documentations shows that the blood cell counter was working well.

Sample 7, obtained in Daegu before the race, shows a typical and undisputable evidence of a pre-competition OFF phase: OFF score is at her top (135), hemoglobin has risen to 159 (17 g/L more than 45 days before) and reticulocytes are very low again (0.16%). Such results provide the strongest evidence of suspect of the whole profile.

Sample 8, collected 40 days after, during a stay at moderate altitude, suggests a new phase of erythropoietic stimulation and confirms a the use of ESA. Reticulocytes are now high (2.93%) and hemoglobin is quite up for a woman. RDW is strongly increased, indicating that different waves of newly produced red blood cells are being released into the blood. A similar reticulocyte and hemoglobin pattern is also present in sample 10, and repeats the features of sample 5, suggesting that this Athlete was used to inject EPO during training periods (and to suspend it before important competitions). This is not surprising, since it is known that athletes do use ESA not only as a performance-enhancing drug, but also to train harder and to accelerate recovery from hard training.

Ferritin

The ferritin level of 5027 mcg/L, measured on 30-8-2011, is strikingly higher than the population upper reference values of 6-159 mcg/L It indicates iron overload, which can damage many organs and increase the risk of infections. Ferritin concentration may increase during severe inflammatory states, but is not modified by intensive and prolonged exercise

A marked increase in serum ferritin, due to parenteral iron administration, has been found among male professional road cyclists, with average values around 300 mcg/L. The ferritin concentration of 5027 observed in this Athlete is at least five times higher than the highest values found in those male cyclists

Even in hereditary hemochromatosis, a value above 1000 is considered a marker of risk of advanced liver disease, and an indication for liver biopsy. Ferritin ranges in groups of homozygous females with severe hemochromatosis have been reported between 242-2682 ... and 122-395

Thus, in the absence of an advanced form of hemochromatosis, the value of ferritin of 5027 mcg/L necessarily reflects intravenous administration of high doses of an iron preparation. Although it cannot be considered a direct proof of former or actual doping, such practice in athletes has been associated with the use of EPO or analogues ... and is an indirect clue which supports the suspect of blood doping with ESA intake.

Conclusion

The variation in hemoglobin concentration and the repeated alternance of severe reticulocytopenia with reticulocytosis in this Athlete cannot be explained by a known hematologic disorders, in the absence of anemia. Altitude training does not seem relevant in this profile, because it does not induce low reticulocyte counts.

The most probable explanation, in my opinion, is that the profile is the result of the alternance of phases of stimulation (OFF score low) and inhibition (OFF score high), in a general context of the use of a prohibited substance or a prohibited method”;

iii. Professor Michel Audran⁵ noted in the opinion of 18 June 2012 the following:

“Comments

- *The increase of HGB of 23 g/l in less than 30 h between samples 1 and 2 isn't physiologic. However the HGB value of sample 1, 137 g/l, and the low RET% corresponding value, 0.21 is a problem.*
- *The increase of HGB, the decrease of RET% and in consequence the increase of OFF-score value between samples 6 and 7 is characteristic of blood manipulation.*
- *Such drop of RET% are noticed on samples 1 and 2 and sample 3 which are samples taken close to a competition, but sample 5 is far enough of a competition.*
- *There is no relation between HGB and RET%:*
 - sample 2: HGB 150 g/l, RET% 0.15*
 - sample 8: HGB 150 g/l, RET% 2.93*
 - sample 4: HGB 141 g/l, RET% 0.31*
 - sample 9: HGB 141 g/l, RET% 1.31*
 - sample 5: HGB 142 g/l, RET% 0.12*
 - sample 6: HGB 142 g/l, RET% 0.94*

The totally abnormal high value of ferritin is also in favour of blood manipulation”.

11. On 19 September 2012, the IAAF forwarded the Initial Review to ARAF and, *inter alia*, in accordance with the IAAF ADR, requested that the Athlete be given an opportunity to explain her abnormal blood profile.
12. On 15 October 2012, the Athlete, instead of providing the requested explanation, signed a voluntary Provisional Suspension Form.
13. IAAF, then, in the subsequent period, sent several letters to ARAF reminding it that it had to review the case of a possible anti-doping rule violation by the Athlete. On 27 June 2014, finally, IAAF sent a notification to ARAF pointing out that, in violation of the applicable IAAF ADR, ARAF had not reviewed the case of the Athlete and informed it that, in the absence of such review by a set deadline, IAAF would take the case to the Court of Arbitration for Sport (the “CAS”) in accordance with the pertinent provisions of the IAAF ADR.
14. On 8 August 2014, ARAF referred the matter to RUSADA, requesting it to review the case, conduct hearings with the Athlete’s participation and decide whether an anti-doping rule

⁵ Professor at the biophysical and bioanalysis laboratory of Faculty of Pharmacy, University of Montpellier I, France.

violation had been committed.

15. Following ARAF's referral, RUSADA submitted the ABP of the Athlete to three other independent experts, who provided the following opinions:

i. Professor Robin Parisotto⁶ observed on 9 November 2014 the following:

“Overall there are four distinct features in this profile that require explanation and are outlined below.

Observation 1

The overall variability in Haemoglobin (Hb) measures is 16.0 % (137 – 159 g/L). It has been documented (Damsgaard R et al 2005 4) that variations in Hb exceeding 15% between blood samples from elite endurance athletes would be indicative of blood manipulation. There is a tendency for higher Hb values in PRE and INC samples with the highest value noted in sample 7 (159: PRE – World Champs 2011) which was higher than all other Hb values including OOC samples.

Observation 2

Samples 1, 2, 3, 4, 5 and 7 demonstrate very low reticulocyte levels of 0.21, 0.15, 0.14, 0.32, 0.12 and 0.16% respectively (significantly below the normal range lower limit of 0.5%) resulting in very high OFF-scores of 109.5, 126.8, 124.6, 107.1, 121.2 and 135.0 (significantly above the normal range high limit of 94.0). Indeed samples 2, 3, and 7 OFF-scores exceed the 1:10000 false positive rate at sea level while sample 7 OFF-score exceeded the 1:10000 false positive rate at altitude. It was noted that the highest OFF-scores coincided with INC and PRE samples 2, 3 and 7. Furthermore it was evident that despite altitude exposures prior to or during all sampling periods, other OFF-scores never reached the levels seen in samples 2, 3 and 7. Therefore it is curious why such extreme OFF-scores have been restricted to those samples around or during competition times.

In normal healthy individuals normal Hb levels are associated with normal reticulocyte levels. There are few if any medical and/or physiological phenomena (such as a medical blood transfusion) which are associated with combinations of normal Hb levels with such abnormally low retic levels. For instance, it is known that permanent high altitude dwellers with relatively high Hb levels descending to sea level appear to have preferential destruction of reticulocytes, a term known as neocytolysis possibly resulting in high Hb and low reticulocyte levels However, as this athlete indicated there has only been exposure, to what could be best described as moderate altitude levels (up 2200m) during this time and only for a maximum period of 4 weeks it is unlikely that such abnormally low reticulocyte levels in samples 1, 2, 3, 4, 5 and 7 are a consequence of altitude exposure. The pattern of markedly depressed reticulocytes observed in these samples are typical of that seen post r-HuEPO administration ... and/or post transfusion

Observation 3

The extremely high retic value of 2.93% in sample 8 is in stark contrast to all other retic values particularly those observed in samples 1, 2, 3, 4, 5 and 7. This could either indicate a period of accelerated erythropoiesis due to the exogenous administration of erythropoietic stimulating agents (ESA's) or autobleed, although the Hb value has only slightly decreased from the previous sample. Nevertheless the magnitude of the level of retics in sample 8 is somewhat suspicious in light of the athlete having

⁶ Australian Institute of Sport, Canberra, Australia.

predominately very low retic levels in all previous samples.

Observation 4

A probable doping scenario is also reflected in the ABP files in which Hb (87%), reticulocytes, OFF-scores and ABPS have resulted in probabilities of 100%.

NOTE 1: While the data for OOC sample 6 has been retained for the purposes of documentation in this report it has been omitted with regards to the conclusion and in making the final recommendation i.e. the omission of values for this sample had no bearing on the conclusions and recommendation made. In this sample the MCHC value of 30.5 indicates significant error with the MCV value (102.9) which is significantly higher than all other MCV values. This has had the effect of falsely increasing the Hct value and therefore falsely decreasing the MCHC value. This error could either be due to incorrect sample handling or instrument error.

NOTE 2: There were two samples (2 and 10) where the white blood cell count (WBC) was significantly elevated. For sample 2 in particular the WBC was 24.7 which is very high and usually indicates significant pathological conditions such as infection and/or inflammation. The athlete however has not indicated on the Doping Control Form the presence of any illness. Another cause of such high WBC's also is in post-exercise scenarios. The sample has apparently been collected during an INC phase as is indicated on the Doping Control Form but the athlete has indicated that she had not exercised in the previous two hours. It would be prudent to check if this sample was however collected on competition day as it was collected at a somewhat unusual time of 1600 hrs or so. It could be that the athlete had competed that morning and was still showing signs of inflammation. There was no material effect on the outcome of this review however perhaps as a potential duty of care issue, this should be followed up given the athlete had another occasion where the WBC was elevated.

Comment on reticulocyte analysis

It was also noted that in samples 1, 4, 5 and 7 the duplicate retic analysis breached WADA Guidelines in that there was a greater than 15% difference between duplicate retic values. This however can easily be mitigated by accepting that the higher of the two values be regarded as the 'official' result for that sample. This also would be in favour of the athlete. Irrespective which value is considered however it does not change the opinion of the reviewer as all duplicate values are still abnormally low”;

and reached the following conclusion and recommendation:

“The author believes that the overall variation in Hb measures of 137 and 159 (16% difference) is beyond normal physiological limits but more importantly the higher Hb values have occurred in INC and PRE samples. Coupled with the markedly depressed reticulocyte values in sample 1, 2, 3, 4, 5 and 7 the findings are strongly suggestive of previous exogenous erythropoietic stimulation and/or blood transfusion. In addition the extremely high retic level noted in sample 8 does not appear in context with the athlete's overall profile. As the athlete had not indicated on the Doping Control Form that there were no blood donations or traumatic blood loss this also needs explanation as this could indicate autobleed.

In the absence of any possible underlying medical conditions and/or other reasonable explanations the author of this report recommends that this case be considered for an Anti-Doping Rule Violation under the WADA code 2.2 – Use of a Prohibited Substance or a Prohibited Method. This is however conditional on the basis that the remaining documents as listed above be provided to the reviewer to make a more fully informed and confident recommendation”;

- ii. Dr Mario Zorzoli⁷ indicated on 27 November 2014 that “the data of the athlete bear several abnormal features” for the following reasons:

“Abnormal %RET and OFF sequence

The athlete shows two distinct set of values ...: the 6 values which are related to competitions (samples collected either pre-competition or in-competition ...) from 2009 to 2012 have very low %RET, within 0.15% and 0.86%, with a median value of 0.185%, while the 6 values of samples collected out-of-competition ..., between 2011 and 2012 are within 0.12% and 2.93%, with a median value of 1.125%. This difference of values, and especially the increase of 1700% between sample 7 and 8 (from 0.16% to 2.93%) are clearly not normal. Such low values of %RET also leads to great variations of OFF values, with the athlete showing higher OFF values when tested at the time of the competitions (either in- or pre-competition) ..., with mean values of 113.8 and 80.7 respectively. Such a pattern, and this difference of means, is to be considered abnormal.

A similar different pattern of %RET and OFF values is observed when analyzing samples 1-7 ..., collected between 15.8.2009 and 30.8.2011 and samples 8-12 ... which have been collected between 8.10.2011 and 10.8.2012 Interesting, during both these periods there are samples collected in relation to competitions and samples collected out-of-competition.

Such a high variability of the registered %RET and OFF values leads to a sequence which displays a high statistical degree of abnormality.

Evolution of %RET and OFF

More in details, sample 1, 2 and 7 show an abnormally low %RET at 0.21%, 0.15% and 0.16% respectively. If the first value is even below the expected population limit, the evolution of the results of the samples which have been collected afterwards clearly shows that the athlete does not have “normal and constant low values”, because especially after October 2011 his %RET have dramatically increased. By the way, beside some medical conditions, it is not normal to have such a variations in %RET, which culminated in a difference of more than 1700% between sample 7 and 8. On one side, beside some medical conditions, there are no “natural” reasons to have such a low reticulocytes count. Such a constellation of low %RET and normal-high HGB leads to an increased OFF value. The significance of an elevated OFF value is considered to be the consequence of a previous blood manipulation which increased the number of circulating red cells, and therefore HGB, either by ESA or by transfusions. To counteract this change in the body homeostasis, the organism reacts by shutting down its own production of red cells (negative feed-back) which is evidenced by the suppressed number of %RET. Consequently, such a combination of elevated HGB and suppressed %RET is not normally found in nature, and cannot be the consequence of a medical condition.

On the other side, an extremely high %RET (2.93%) cannot neither be the consequence of a red cell pathology (otherwise %RET would constantly remain elevated), nor the consequence of a loss of red cells, because on sample 8 HGB shows its second highest value of the whole profile (15.0 g/dL). Likewise, exposure to altitude doesn't seem to be the reason for such an increase of %RET for two reasons: first because no scientific study has ever demonstrated that exposure to altitude at 1700- 1900m for 3 weeks could stimulate the bone marrow in such a way; second because when the athlete has been exposed to altitude in similar, or even more favourable conditions (6 weeks at an altitude of 2200m), the behaviour

⁷ Geneva, Switzerland. Dr Zorzoli is *inter alia* health manager at the International Cycling Union (UCI).

of the %RET was completely the opposite, reaching the 2nd lowest value at 0.14% (samples 3). It is therefore to be attributed to the use of blood doping agents as ESA.

Such a variable evolution of %RET, and consequently of OFF values, seems therefore to be the consequence of blood manipulations like the use of erythropoiesis stimulating agents and/or blood transfusions.

Samples 1, 2, 6, 7, 8, 9 and 10

As mentioned above, several samples exceeded the expected limits (population and individual) for many of the measured parameters (HGB, OFF and %RET): - Sample 1, 2, 6, 8, 9 and 10 exceed the limits for %RET and OFF; - Sample 7 exceeded the limit for HGB and OFF;

More specifically, samples 2 and 7 showing abnormally low %RET were associated with the two highest HGB and consequently the two highest OFF values. As previously discussed, such a constellation of results seems therefore to be the consequence of previous blood manipulations such as the use of erythropoiesis stimulating agents and/or blood transfusions, especially when considered that they were obtained in relation to competitions.

Likewise, the extreme high values of %RET in sample 8, 9 and 10 is compatible with the use of ESA.

Conclusions

The main elements of abnormalities of this profile are related to the extremely variable %RET and OFF values. In fact, low %RET and high OFF are mainly found at the time of competitions when compared to out-of-competition samples. This is compatible with what we would expect to observe when blood manipulation takes place out-of-competition, and is confirmed by the high %RET measured on several of the out-of-competition samples (the 4 highest %RET were on samples collected out-of-competition). Additionally, there is a change in the evolution of %RET which display higher results from July 2011 when compared to those collected since August 2009.

It is therefore my opinion that the likelihood of these abnormalities being due to blood doping, such as the use of ESA and/or blood transfusion is very high. In contrast, the likelihood of such deviations being caused by a medical condition, altitude exposure or any other condition is low. As such, I therefore recommend requesting the athlete's explanations for his blood values.

Such a scenario is consistent, outside an alternative credible explanation from the athlete, with the evolution of haematological parameters observed when blood doping is administered (blood transfusion and/or erythropoiesis-stimulating agents)";

- iii. Professor Pavel Vorobiov⁸ stated on 10 December 2014 the following (the "Vorobiov Opinion"):

'Estimation of blood profile

The profile demonstrates the different fluctuations of ABP parameters in different samples.

The level of the HGB stays within the normal range for women 120-160g/L. The level of RET % in samples No 1, 2, 3, 4, 5 and 7 was below lower limit of normal range (0,21%; 0,15%;0,14%;0,32;0,12% and 0,16% respectively), and in sample 8, the RET% is above of the normal range (2,93%) (the normal physiological limits are 0,5-2,5%). Respectively OFF-score went

⁸ Professor, Department of Hematology and Geriatrics, First Medical University in Moscow.

above the normal range for women (37,2-94,0): in samples No 1, 2, 3, 4, 5 and 7 values are 109,5; 126,8; 124,6; 107,1; 121,2; 135 and 95,7, respectively.

The overall variability in Haemoglobin (HGB) measures is 16.0% (137 – 159 g/L). It has been documented that variations in HGB exceeding 15% between blood samples from elite endurance athletes would be indicative of blood manipulation. There is a tendency for higher HGB values in pre and INC samples with the highest value noted in sample 7 (159: PRE – World Cup 2011) which was higher than all other HGB values including OOC samples. The level of HGB notably increases from 142g/L (sample 6) to 159g/L within short period of 1,5 month. At the same time we observe decrease of RET% from the physiological level 0,94% to very low value 0,16 (0,20)%.

Samples 1, 2, 3, 4, 5 and 7 demonstrate very low reticulocyte levels of 0,21, 0,15, 0,14, 0,32, 0,12 and 0,16% respectively (significantly below lower limit of normal range 0,5%) resulting in very high OFF-scores of 109,5, 126,8, 124,6, 107,1, 121,2 and 135,0 (significantly above high limit of normal range of 94,0). It was noted that the highest OFF-scores coincided with INC and PRE samples 2, 3 and 7. Furthermore it was evident that despite altitude exposures prior to or during all sampling periods, other OFF-scores never reached the levels seen in samples 2, 3 and 7. Therefore it is curious why such extreme OFF-scores have been restricted to those samples around or during competition times.

In normal healthy individuals normal HGB level is associated with normal reticulocyte level. It is known that permanent high altitude dwellers with relatively high HGB level descending to sea level appear to have depression of reticulocytes.

However, as this athlete indicated there has only been exposure to what could be best described as moderate altitude levels (up 2200m) during this time it is unlikely that such abnormally low reticulocyte levels in samples 1, 2, 3, 4, 5 and 7 are a consequence of altitude exposure. Such pattern of markedly depressed reticulocytes observed in these samples are typical of that seen post r-HuEPO administration and/ or post transfusion.

The extremely high RET value of 2,93% in sample 8 is in stark contrast to previous samples. Such stimulation of erythropoiesis may indicate the exogenous administration of EPO: the reticulocytosis takes place and the level of HGB has not risen yet. The same stimulation may be determined by autobleed, although the HGB value has only slightly decreased from the previous sample.

Sample 6 also attracts attention as the MCHC value 30,5 of this sample indicates significant error with the MCV value (102,9). This error could either be due to incorrect sample handling or instrument error however its exclusion does not change the position of the author.

Conclusion

The author believes that the overall variation in Hb measures of 137 and 159 (16% difference) is beyond normal physiological limits but more importantly the higher HGB values have been indicated in INC and pre-competition samples. Coupled with the markedly depressed reticulocyte values in sample 1, 2, 3, 4, 5 and 7 the findings are strongly suggestive of previous exogenous erythropoietic stimulation and/ or blood transfusion.

In addition the extremely high RET level noted in sample 8 does not appear in context with the athlete's overall profile. As the athlete had not indicated in the Doping Control Form that there were blood donations or traumatic blood loss this also needs explanation as this could indicate autobleed.

The author of this report recommends that this case be considered for an Anti-Doping Rule Violation under the WADA code 2.2 – Use of a Prohibited Substance or a Prohibited Method”.

16. On 11 December 2014, RUSADA informed the Athlete that, based on the further expert review, it was proceeding with a disciplinary case against her based on the atypical profile in her ABP, and gave the Athlete an opportunity to provide an explanation in that respect.
17. On 12 January 2015, the Athlete replied that, as she was unable to scientifically rebut the experts' conclusions, she admitted the charges brought against her and asked for the hearing to be conducted in her absence.
18. On 20 January 2015, the Disciplinary Anti-Doping Committee of RUSADA (the "Anti-Doping Committee") held a hearing in the Athlete's absence. The IAAF was not a party to the RUSADA proceedings and was not asked to participate in the proceedings.
19. On 20 January 2015, the Anti-Doping Committee issued the decision No. 4/2015 (the "Decision"), which, in its unchallenged English translation, reads as follows:
 - "1) *The Athlete OLGA KANISKINA is found guilty of anti-doping rule violation (Art 32.2. (b) of the IAAF Anti-Doping Rules which were in force on the date of anti-doping rule violation);*
 - 2) *The Athlete OLGA KANISKINA is declared ineligible for a period of 3 (three) years and 2 (two) months commencing from 15 October 2012 according to the Art 40.6 of the IAAF Anti-Doping Rules which were in force on the date of anti-doping rule violation.*
 - 3) *Pursuant to the Art 40.9 of the IAAF Anti-Doping Rules which are in force from 1 January 2015 and taking into account fairness and proportionality the competitive results of the Athlete OLGA KANISKINA are declared disqualified within the following periods:*
 - *15 July 2009 – 16 September 2009;*
 - *30 July 2011 – 8 November 2011"*
20. In the Decision, the Anti-Doping Committee found that the anti-doping rule violation described in Article 32.2(b) of the applicable version of the IAAF ADR [*"Use or Attempted Use by an Athlete of a Prohibited Substance or a Prohibited Method"*] had been committed, and sanctioned the Athlete with a period of ineligibility in the measure it found proper and proportionate, starting from the date of the provisional suspension. With respect to the "selective" disqualification of results imposed in the Decision, the Anti-Doping Committee reasoned as follows:
 - "48. *Pursuant to Art. 40.8 IAAF Anti-Doping Rules which were in force in 2009-2012 (hereinafter referred as "Old IAAF ADR"), i.e. within the period when the IAAF was collecting the blood samples for ABP purposes, all competitive results of the Athlete from the date of anti-doping rule violation through the date of provisional suspension shall be disqualified.*
 49. *In the meantime, on 1 January 2015 new IAAF Anti-Doping Rules entered in force ("New IAAF ADR") where the results disqualification rules have been amended. In New IAAF ADR this provision contains additional clause which requires to disqualify all competitive results of the Athlete "unless fairness requires otherwise".*

50. *The Commission notes that although the New IAAF ADR were not effective in 2009-2012, the Commission is entitled to apply it in the present matter on the basis of “lex mitior” which is foreseen by the Art 49 of the New IAAF ADR.*
51. *“Lex mitior” allows the hearing body to apply the rules which entered in force after an anti-doping rule violation had been committed provided that such rules establish more preferable position for a person which is subject to disciplinary proceedings. Thus, the Commission suggests that the New IAAF ADR contain more preferable position for a person under disciplinary proceedings allowing to disqualify competitive results unless fairness requires otherwise.*
52. *Then, the Commission shall set up an approach for disqualification of results with “fairness” principle. In this regard the Commission has to refer again to the CAS jurisprudence in similar cases in sports other than athletics which rules allowed heretofore to “selectively” disqualify competitive results of the athletes obtained after the date of anti-doping rule violation.*
53. *In CAS 2010/A/2235 [...] the CAS Panel ruled that the disqualification shall be applied only to those results which were likely to be affected by the anti-doping rule violation.*
54. *In furtherance of this approach the CAS Panel determined the samples which showed abnormal blood values and disqualified the results which had been obtained in the period between these 2 (two) samples plus 1 (one) month after the last “abnormal” sample.*
55. *The Commission suggests that this rationale slightly amended keeping in mind peculiarities of this case may serve as a basis for disqualification of results in the present matter as well. The Commission has thoroughly examined the opinions of 6 IAAF and RUSADA experts and determined the samples with abnormal blood values. Given that anti-doping organization shall have the burden of proof when establishing an anti-doping rule violation and the standard of proof shall be greater than mere balance of probabilities but less than beyond reasonable doubt, the Commission decides to consider as “abnormal” the samples which contained abnormal values according to the opinions of not less than 5 experts.*
56. *Under such approach the Commission declares abnormal the samples #1 (15 August 2009), #2 (16 August 2009), #7 (30 August 2011) and #8 (8 October 2011). Therefore, the Commission according to “fairness” principle shall obligatory disqualify the competitive results of the athlete within the period which commences 1 month prior to the date of abnormal sample and ends 1 month after the date of abnormal sample, and other results which may be affected by the anti-doping rule violation”.*
21. The Decision was notified to IAAF, with an English translation, on 9 February 2015.
- 2. THE ARBITRAL PROCEEDINGS**
- 2.1 The CAS Proceedings**
22. On 25 March 2015, IAAF filed a statement of appeal with the CAS, pursuant to Article R48 of the Code of Sports-related Arbitration (the “Code”), to challenge the Decision, naming ARAF

and the Athlete as respondents.

23. The statement of appeal had attached 2 exhibits and contained the designation of Mr Romano Subiotto, QC as an arbitrator.
24. On 1 April 2015, the CAS Court Office forwarded to ARAF and the Athlete the Appellant's statement of appeal. In the letter to the parties, the CAS Court Office noted that distinct appeals had been brought by IAAF to challenge decisions rendered by RUSADA in disciplinary proceedings regarding different athletes with regard to their atypical ABP profiles (the "Other Appeals"), which had been registered as follows:
 - CAS 2015/A/4005, *International Association of Athletics Federations (IAAF) v. All Russia Athletics Federation & Sergey Kiryapkin*
 - CAS 2015/A/4006, *International Association of Athletics Federations (IAAF) v. All Russia Athletics Federation & Yuliya Zaripova*
 - CAS 2015/A/4007, *International Association of Athletics Federations (IAAF) v. All Russia Athletics Federation & Sergey Bakulin*
 - CAS 2015/A/4009, *International Association of Athletics Federations (IAAF) v. All Russia Athletics Federation & Valeriy Borchin*
 - CAS 2015/A/4010, *International Association of Athletics Federations (IAAF) v. All Russia Athletics Federation & Vladimir Kanaikin*

and invited the parties to inform the CAS Court Office whether they agreed to submit the case regarding the Athlete to the same Panel to be appointed also for the Other Appeals.

25. On the same day, 1 April 2015, the CAS Court Office informed RUSADA that an appeal had been lodged against the Decision in the case concerning the Athlete and indicated that the appeal had not been directed at RUSADA. The CAS Court Office, at the same time, informed RUSADA that, if it intended to participate in the arbitration, it had to file with CAS an application to this effect.
26. On 10 April 2015, RUSADA confirmed, in a letter to the CAS Court Office, that it was ready "*to participate as a party in this case to defend its decision*".
27. In a letter of 13 April 2015, the Second Respondent appointed Mr Mika Palmgren as an arbitrator and confirmed her agreement that the proceedings in this case and in the Other Appeals be referred to the same Panel.
28. On 15 April 2015, the First Respondent informed the CAS Court Office that it agreed to the participation of RUSADA in this arbitration and that the case of the Athlete be submitted to the same Panel appointed for the Other Appeals.
29. On 16 April 2015, the Second Respondent confirmed its agreement to the intervention of RUSADA.

30. On 17 April 2015, the Appellant indicated to the CAS Court Office that it had no objections to the intervention of RUSADA in this arbitration.
31. On 20 April 2015, as a result, the CAS Court Office advised the parties that RUSADA was considered as a party to the arbitration, and that the same Panel would be appointed to hear the case of the Athlete as well as the Other Appeals.
32. On 20 April 2015, the First Respondent agreed to the appointment as an arbitrator of Mr Palmgren.
33. On 27 April 2015, RUSADA also agreed to the appointment of Mr Palmgren.
34. On 4 May 2015, within an extended deadline, the Appellant submitted its appeal brief, in accordance with Article R51 of the Code, together with 26 exhibits, which included, *inter alia*, an additional expert opinion dated 19 March 2015 (the “Joint Expert Report”) and a further expert opinion dated 10 April 2015 (the “Further Expert Opinion”) jointly signed by Professor Schumacher, Professor d’Onofrio and Professor Audran, the authors of the Initial Review.
35. On 8 May 2015, the Appellant’s appeal brief was forwarded to the Respondents. Correspondence then followed with respect to the deadline for the submissions of the Respondents’ answers.
36. On 14 July 2015, the CAS Court Office informed the parties, on behalf of the President of the CAS Appeals Arbitration Division, that the Panel had been constituted as follows: Prof. Luigi Fumagalli, President of the Panel; Mr Romano Subiotto, QC and Mr Mika Palmgren, arbitrators.
37. The Respondents, within extended deadlines, submitted their answers, in accordance with Article R55 of the Code, as follows:
 - i. on 11 July 2015, the First Respondent filed its answer, with no exhibits attached;
 - ii. on 24 July 2015, the Second Respondent filed her answer, together with 9 exhibits and a list of experts to be heard (Dr. Max Testa, Dr. Roberto Corsetti, Dr. Nicolas Faber, Dr. Bernard Vandengiste, Professor Pavel Vorobiov and Professor Sergey Rumyantsev);
 - iii. on 10 July 2015, the Third Respondent filed its answer, together with 6 exhibits.
38. In a letter of 11 September 2015, the Appellant, noting some submissions contained in the Second Respondent’s answer, in which “*the athlete ... would appear to be arguing that the ABP concept is not sufficiently reliable or scientifically sound, thereby casting doubt as to whether the violation against the athlete should be upheld*”, requested that the Athlete be required “*to clarify immediately*” some issues in that respect.
39. On 17 September 2015, the CAS Court Office advised the parties that the Panel, having considered the IAAF’s request of 11 September 2015, had decided not to allow a second round of written submissions and to hold a hearing where the parties would have the opportunity to present their respective cases, as outlined in the written submissions.

40. On 22 September 2015, the Appellant insisted on its request that the Second Respondent be required to clarify her position on the issues mentioned in the letter of 11 September 2015.
41. In a letter of 25 September 2015, the parties were informed that the Panel had decided to hold a hearing in Lausanne, Switzerland, on 2 and 3 December 2015.
42. On 1 October 2015, the Appellant reiterated its requests of 11 and 25 September 2015.
43. On 8 October 2015, the CAS Court Office advised the parties that the Panel had decided to confirm its decision of 17 September 2015.
44. On 13 November 2015, the CAS Court Office transmitted to the parties a draft hearing schedule, indicating that the case of the Athlete would be discussed simultaneously with the discussion on the Other Appeals, with the sole exception of case CAS 2015/A/4006, that, as per a request of the athlete involved in that case, would be discussed separately.
45. Correspondence was then exchanged between the parties as to the organization and the schedule of the hearing.
46. On 24 November 2015, and for such purposes, a conference call was held with the participation of the President of the Panel and the parties' counsel. During this conversation, the parties agreed that the case CAS 2015/A/4006 would be heard on a different date, and therefore that on 2 and 3 December 2015 the case of the Athlete would be discussed together with the Other Appeals, with the exception of case CAS 2015/A/4006. In that respect, and as a result, the President of the Panel made it clear that, in order to safeguard the integrity of all proceedings, the award in the arbitration regarding the Athlete would be issued only after all Other Appeals (including CAS 2015/A/4006) were heard, even though it was clear that every case would be decided only on the basis of its specificities, and of the parties' respective pleadings and evidence. In the conference call, discussions also took place with respect to the Second Respondent's request that her experts, including those who had not provided an expert report, be heard last.
47. As a result, the Panel, in a letter dated 24 November 2015, advised the parties that "*experts and 'counter-experts' [would] be allowed to attend the hearing ... at the same time and to intervene under the control of the Panel*", and set a deadline for the Second Respondent to file a list of issues, as detailed as possible, on which her expert(s) intended to express their opinion.
48. In a letter of 25 November 2015, the Second Respondent "*strongly*" protested against the procedural steps mentioned in the CAS letter of 24 November 2015, asking the Panel to reconsider them. In particular, the Second Respondent maintained: that it was not acceptable that a decision on her case be rendered only after hearing case CAS 2015/A/4006, since the cases should be decided "*totally separately*"; that the Athlete cannot be forced to reveal her defence strategy before the hearing, and therefore that no list of issues for the experts could be requested; and that the experts designated by the Second Respondent had to be heard after the experts called by the Appellant and that the Appellant's experts should not be allowed to attend

the hearing before and after their testimony. In the alternative, the Athlete requested to be provided with copy of the other parties' submissions in case CAS 2015/A/4006.

49. On the same 25 November 2015, the CAS Court Office, writing on behalf of the Panel, advised the parties of the following:

“As repeatedly mentioned during the conference call of yesterday, all cases will be decided by the Panel on the basis of their individual peculiarities and of the parties’ submissions in their respect. No argument raised in one case will be used in another case, if not specifically raised also in such other case. Therefore, the request of communication to Dr Valloni of the submissions and documents filed by the other parties in case CAS 2015/A/4006 is denied.

The Panel’s intention to issue the arbitral awards in all cases after all cases are heard does not contradict the foregoing and does not mean that the cases concerning the athletes represented by Dr Valloni will be decided after hearing the case of Ms Zaripova. The intention to issue all the arbitral awards at the same time concerns only their notification to the parties and is intended to protect the integrity of all proceedings.

The Panel does not treat the experts indicated by the parties as being part of the public. Therefore, the Panel has decided to allow their attendance at the hearing when another expert is heard, in order to answer the questions that the Panel or all parties may have by way of “experts’ conferencing”. This rule applies to all the experts: therefore, the experts appointed by the athletes are invited to attend when the experts of the Appellant will be heard and will have the opportunity to intervene and contradict the statements of the Appellant’s experts.

The Panel is fully determined to guarantee the athletes’ right to be heard. Therefore, the Panel allows the athletes (and their counsel) to discuss with the experts they have appointed any issue relevant to their cases. In the list to be provided ... therefore, the athletes can indicate any issue they wish. At the same time, the Panel is striving to find a way to ensure that, on the basis of the list of issues that the athletes are invited to provide, it can benefit as much as possible from the presentations of the athlete’s experts. In the same way, the Panel is aware of the Appellant’s claim not to be taken by surprise. As a result, the athletes’ request that the Panel reconsiders its decision is denied”.

50. In a letter of the same day, 25 November 2015, the First Respondent expressed its support to the Second Respondent’s position.
51. On 27 November 2015, the CAS Court Office, on behalf of the President of the Panel, issued an order of procedure (the “Order of Procedure”), which was accepted and countersigned by the Appellant, ARAF and RUSADA. The Second Respondent declined to sign the Order of Procedure.
52. On 27 November 2015, the Appellant expressed its position and dissent with regard to the Second Respondent’s letter of 25 November 2015.
53. In a letter of 27 November 2015, the Third Respondent informed the Panel that WADA had declared RUSADA “non-compliant” with the WADC and that it had to “immediately cease all anti-doping activities”. Therefore, it requested the CAS to suspend the hearing scheduled “till clarification of RUSADA’s status”.

54. On 27 November 2015, the Second Respondent reiterated her rejection of the procedural measures, alleging that they “clearly favour the Appellant and undermine the Respondents’ rights to a fair trial in an intolerable way”. At the same time, the Second Respondent raised another issue “which heavily undermines [the] right [of the Athlete] to a fair trial” as follows:

“As WADA suspended RUSADA ... with immediate effect, WADA seems to think that RUSADA is not entitled to attend the hearings of 2 and 3 December 2015 and is not entitled to act in the proceedings. This means that RUSADA cannot defend the decisions against which the Appellant appealed and that the proceedings are led with a Respondent 3 missing. This is unacceptable and this does also affect the position of the Respondents since RUSADA is not there to defend the decision taken. The proceedings at hand cannot be continued if [RUSADA] is not entitled to act and defend itself. Apart of that, the decision to suspend RUSADA is not final, hence another reason to suspend the proceedings up to the moment there is clarify about the position of RUSADA. Hence, we clearly support the position of RUSADA to wait until further clarification.

Furthermore, the decision of WADA to suspend RUSADA triggers an important issue about the jurisdiction of the CAS. Indeed, Respondents think that a suspension lift the arbitration clause as RUSADA is no longer considered by WADA as a party and does not have any rights in these proceedings. Therefore, WADA’s decision affected the arbitration clause and Respondents do not accept CAS jurisdiction anymore and is not accepting any change in the way the procedure is supposed to be run”.

55. On 27 November 2015, the Panel denied the Athlete’s request to cancel the hearing scheduled for 2 and 3 December 2015, confirmed a deadline for the Second Respondent’s filing of a list of issues that would be discussed by her experts, and invited the other parties to comment on the remaining issues raised by the Athlete and by RUSADA in their letters of 27 November 2015.

56. On 30 November 2015, the CAS Court Office, writing on behalf of the Panel with respect to the recent correspondence and chiefly with regard to the invitation to the Athlete (and to all the athletes whose cases would be heard at the upcoming hearing) to provide a list of the issues, as detailed as possible, that would be discussed by her (their) experts, specified the following:

“In order to avoid any misunderstanding, the Panel wishes to clarify the point, and provide some guidance with respect to the level of detail of such list. More specifically, the Panel confirms that it is inviting the athletes to provide only a description of the object of the experts’ declarations of the same kind and detail as that provided by the Appellant (see for instance §§ 40 and 41 of the appeal brief in CAS 2015/A/4005). At the same time, it is confirmed that the athletes can indicate any issue relevant to the case they wish”.

57. On 30 November 2015, the Appellant forwarded a communication received from WADA confirming that “RUSADA’s non-compliant status does not prevent it from appearing as a respondent party to on-going CAS proceedings”.

58. On 1 December 2015, the Second Respondent, while again noting the “Panel’s denial to grant the right to a fair defence” and criticizing “the latest decisions of the Panel which clearly favour the Appellant”, listed the issues to be discussed with the experts as follows:

- “1) *Accuracy of the Athlete Biological Passport and the method to detect doping*
- 2) *IAAF’s and WADA’s approach on doping cases*
- 3) *Examination of the samples in the cases at hand*
- 4) *Examination of the IAAF’s experts’ opinion in the cases at hand”.*

59. On 1 December 2015, the Appellant reacted to the Second Respondent’s letter of even date objecting to the list of issues submitted by the Athlete and more specifically to the point concerning the “*Accuracy of the Athlete Biological Passport and the method to detect doping*”.
60. A hearing was held in Lausanne on 2 and 3 December 2015, as per the notice in the letter of 25 September 2015. The Panel was assisted by Mr Fabien Cagneux, Counsel to CAS. The following persons attended the hearing:
- i. for the Appellant: Mr Huw Roberts, Mr Nicolas Zbinden and Mr Ross Wenzel, counsel;
 - ii. for ARAF Mr Artem Patsev, counsel;
 - iii. for the Athlete Mr Lucien W. Valloni and Ms Stéphanie Oneyser, counsel;
 - iv. for RUSADA Ms Anna Antseliovich, Head of the RUSADA Results Management Department.
61. At the hearing, after the opening statements of the parties, Professor Schumacher (via video connection), Professor d’Onofrio (physically present) and Professor Vorobiov (via phone connection), *i.e.* experts who had signed written opinions with respect to the Appellant’s case, were heard in direct, cross- and re-direct examination. The Second Respondent indicated that no additional expert mentioned in her answer would appear. The Panel therefore noted that the pre-hearing discussions concerning the Second Respondent’s request to be allowed to hear the deposition also of those experts she appointed (and chiefly of Professor Rumyantsev), who had not signed an expert opinion, had become moot.
62. The contents of the declarations of the experts can be summarised as follows⁹:
- i. Professor Schumacher confirmed the opinion expressed in the Initial Review, in the Joint Expert Report and in the Further Expert Report and explained that EPO increases an athlete’s maximal oxygen uptake (the “VO_{2max}”) by 1% to 4% for a period of up to 4 weeks after the erythropoiesis stimulation, depending on the dosage of its administration, and confirmed that the use of micro-doses over a longer period can produce long-lasting effects. Professor Schumacher declared having appeared before CAS in all major ABP cases, and that he never assisted an athlete in CAS proceedings; however, he underlined that in several occasions, while reviewing ABP profiles, he had expressed an opinion

⁹ This summary does not necessarily follow the order of presentation of the experts and intends only to give an indication of a few points touched at the hearing. The Panel, however, considered the entirety of the declarations rendered at the hearing.

- favourable to the athlete;
- ii. Professor d’Onofrio also confirmed the opinion expressed in the Initial Review, in the Joint Expert Report and in the Further Expert Report, and examined the values contained in the Athlete’s ABP (§ 9 above), underlining that its main feature is the abnormally low RET% count in several of the samples. In addition, Professor d’Onofrio confirmed that in his opinion samples 3, 5 and 10 are abnormal, and that samples 8 and 10 show a stimulation phase, followed by suppression, possibly associated (as for sample 12) with blood reinfusion or dilution. Professor d’Onofrio also confirmed that he had expressed the opinion in 2010 that the panel in charge of the initial review should preferably be composed of 9 members, but that he now thinks that the decision to limit the panel to 3 experts was correct. In this case, the opinions of the experts were unanimous;
 - iii. Professor Vorobiov also examined the values contained in the Athlete’s ABP, confirming the position expressed in the Vorobiov Opinion, and declared that sufficient scientific documentation exists to validate the reliability of the ABP program, even though in his opinion some elements (such as altitude and hydration) should be better considered.
63. During the hearing, the parties specified their arguments in support of their respective petitions. In that context, *inter alia*:
- i. with respect to the issue of CAS jurisdiction:
 - a. the Second Respondent confirmed her objection, announced in the letter of 27 November 2015 (§ 54 above), as based (α) on the unclear position of RUSADA, following WADA’s declaration that RUSADA had to suspend all anti-doping activities under the WADC, and (β) on the suspension of ARAF by IAAF. In this connection, the Second Respondent underlined that she had only agreed to submit to CAS disputes with ARAF and RUSADA;
 - b. the Appellant indicated the basis for CAS jurisdiction and replied to the Athlete’s objection (defined to be “*parasitic*”, “*vexatious*”, “*opportunistic*” and to amount to “*inappropriate procedural conduct*”) by referring to the declaration of WADA, which had confirmed the possibility for RUSADA to participate in the arbitration;
 - c. the First Respondent declared that the suspension imposed by IAAF did not preclude its participation in the CAS proceedings and that it did not agree with the Athlete’s objection;
 - d. the Third Respondent confirmed receipt of a communication on the part of WADA indicating that it could participate in the arbitration;
 - ii. with regard to the merits of the appeal:
 - a. the Appellant underlined, in general terms, the effects of blood doping and the impact of EPO administration on sporting performances and on training as a result of the improvement it causes on the athlete’s VO₂max. With specific reference to the Athlete, then, only doping practices could explain the highly atypical profile of

her ABP, showing at least five doping cycles. At the same time, the Appellant submitted that the appeal is limited to the issue of the retroactive disqualification of results. The Second Respondent's announced challenge to the ABP as a method to detect doping practices was therefore irrelevant, noting that Professor Vorobiov also confirmed the ABP program's reliability. Finally, the Appellant contended that the "fairness exception" to the disqualification of results could not be applied as a matter of law, since the application of the *lex mitior* principle does not allow "cherry-picking" and cannot result in the creation of non-existing rules. In that regard, reference was made to a judgment rendered on 18 July 2013 by the European Court of Human Rights (Grand Chamber) in the case of *Maktouf and Damjanovic v. Bosnia and Herzegovina*, and to a decision of the Swiss Federal Tribunal (ATF 119 IV 145) of 25 June 1993. In any case, in the Appellant's opinion, the Athlete cannot benefit from the "fairness exception", since she was involved in repeated, intentional and severe anti-doping rule violations;

- b. the First Respondent confirmed that the Decision correctly and fairly applied the relevant rules, including the *lex mitior* principle, and properly took into account the limited temporal effect of EPO administration. In any case, according to ARAF, the opinion of the IAAF experts evolved over the times, and IAAF failed to prove its contentions;
 - c. the Second Respondent described the IAAF's submissions to be "*fantasy talking*", since no prohibited substance had ever been detected in the samples provided by the Athlete. In any case, in the Second Respondent's opinion, the Appellant failed to rebut the criticism voiced in the scientific literature against the ABP program and its reliability, still disputed, as an indirect method of detection of an anti-doping rule violation. In addition, the analytical values of the Athlete could be influenced by other factors, such as a virus, or the altitude, which had not been taken into account: as a result, the ABP profile does not show with the required probability level that the Athlete had indulged in doping practices. Moreover, the "fairness exception" had to be applied, in light of its general nature, the necessity of its broad interpretation, and the *lex mitior* principle;
 - d. the Third Respondent emphasised that the "fairness exception" had been properly applied to the disqualification of results in this case, and that no evidence has been offered by IAAF to prove that blood doping had been administered prior to the 2012 Olympic Games. In that respect, RUSADA submitted that the IAAF experts had changed their position, pointing to additional allegedly atypical samples, which they had not mentioned in the Initial Review.
64. At the conclusion of the hearing, after making closing submissions summarizing their respective cases, the Appellant, the First Respondent and the Third Respondent expressly stated that they did not have any objection in respect of their right to be heard and to be treated equally in the arbitration proceedings. The Second Respondent, through counsel, while expressly declaring that she no longer had any objection in respect of her right to be heard and to be treated equally in the arbitration proceedings, only made a reservation to confirm her objection to the CAS

jurisdiction.

65. After the hearing, on the basis of the Panel's directions, the parties timely lodged with the CAS Court Office the quantification of their respective cost claims.

2.2 The Position of the Parties

66. The following outline of the parties' positions is illustrative only and does not necessarily comprise every contention put forward by the parties. The Panel, indeed, has carefully considered, for the purposes of the legal analysis which follows, all the submissions made by the parties, even if there is no specific reference to those submissions in the following summary.

a. *The Position of the Appellant*

67. The IAAF submitted the following prayers for relief in the merits:

- “(i) the IAAF’s appeal is admissible;*
- (ii) the samples collected from Ms Kaniskina on 27 July 2010 (sample 3), 22 May 2011 (sample 5) and 13 April 2012 (sample 10) are abnormal;*
- (iii) the decision of the RUSADA Commission not to disqualify Ms Kaniskina’s results at the 2010 European Championships in Athletics on 28 July 2010, the IAAF Race Walking Cup on 13 May 2012 and the 2012 Olympic Games on 11 August 2012 be set aside; and*
- (iv) all competitive results obtained by Ms Kaniskina from the date of first commission of the anti-doping rule violation (15 August 2009) through to the commencement of her provisional suspension (15 October 2012) be disqualified, with all resulting consequences in accordance with IAAF Rule 40.9; or*
- (v) in the alternative, all competitive results obtained by Ms Kaniskina from the date of first commission of the anti-doping rule violation (15 August 2009) through to the last commission of the anti-doping rule violation (13 April 2012) plus an additional period of one month be disqualified, with all resulting consequences in accordance with IAAF Rule 40.9; or*
- (vi) in the further alternative, all competitive results obtained by Ms Kaniskina that are likely to have been affected by anti-doping rule violations be disqualified (including the 2010 European Championships in Athletics, the 2012 IAAF World Race Walking Cup and the 2012 Olympic Games), with all resulting consequences in accordance with IAAF Rule 40.9; and*
- (vii) the ARAF and Ms Kaniskina are ordered to pay the IAAF the costs that it has incurred in bringing this appeal”.*

68. As already mentioned, IAAF challenges the Decision on only a single point. According to IAAF, in fact, the appeal is not about whether the Athlete has committed an anti-doping rule violation under the IAAF ADR, or about the appropriate period of ineligibility to be imposed on the Athlete for such anti-doping rule violation: *“the sole issue in this appeal concerns the further consequences of Ms Kaniskina’s repeated blood doping in terms of the disqualification of her results in competitions in which she successfully participated during the relevant period 2009-2012 in which she doped”*. In that regard, IAAF

notes that the Athlete's results at the 2010 European Championships, the 2012 Race Walking Cup and the 2012 Olympic Games were not disqualified. In the Appellant's opinion, all results from 15 August 2009 onwards (the date on which the Athlete first committed an anti-doping rule violation) should be annulled, without exceptions, pursuant to Article 40.9 of the IAAF ADR.

69. IAAF considers that the "fairness exception" set forth in Article 40.9 of the IAAF ADR, as contained in Chapter 3 of the IAAF Competition Rules in their 2015 edition (the "2015 IAAF ADR"), should not apply to the Athlete's case for the following reasons:
- i. even though the IAAF accepted in its appeal brief that "*the RUSADA Commission's determination that ... the rule against which the issue of the disqualification of ... results is to be examined, is Rule 40.9 of the 2015 edition of the IAAF Rules*", at the hearing the IAAF argued that the "fairness exception" set forth in Article 40.9 of the 2015 IAAF ADR cannot be applied to the Athlete's case as "*a matter of law*", noting that the IAAF ADR, as contained in Chapter 3 of the IAAF Competition Rules in the 2009 edition (the "2009 IAAF ADR")¹⁰, apply under the "*tempus regit actum principle*" to determine the duration of the applicable ineligibility period, at 3 years and 2 months, pursuant to Articles 40.2 and 40.6 thereof, while Article 40.2 of the 2015 IAAF ADR would have required an ineligibility for 4 years. By contrast, the 2015 IAAF ADR apply with respect to the issue of the disqualification of results under the "*lex mitior*" principle, which is invoked as a justification for the application of the "fairness exception" set forth in Article 40.9 thereof. In the Appellant's opinion, the application of different editions of the IAAF ADR to distinct aspects of the sanction is not consistent with a correct understanding of the "*lex mitior*" principle. This principle requires a comparison of different sets of rules, and the application in its entirety of the more favourable set to the accused, but cannot result in the artificial creation of a non-existent system of rules, composed of provisions belonging to different sets. In support of such contention, the Appellant refers to a judgment rendered on 18 July 2013 by the European Court of Human Rights (Grand Chamber) in the case of *Maktonf and Damjanovic v. Bosnia and Herzegovina* and to a decision of the Swiss Federal Tribunal (ATF 119 IV 145) of 25 June 1993;
 - ii. in any case, there are no grounds for the "fairness exception" to apply in the case of an athlete (like the Athlete) who engaged in intentional, serious and repeated acts of doping over a long period of time. In the Appellant's opinion, the Athlete is not an innocent competitor, who inadvertently ingested a stimulant on a single occasion; this is the case of an athlete whose ABP records a total of at least seven instances of blood doping out of twelve samples collected from her in the period from August 2009 to August 2012 (the abnormal samples being at least 1, 2, 3, 5, 7, 8 and 10), who engaged in intentional and

¹⁰ It is in that respect to be underlined, as the parties acknowledged in their submissions, that the subsequent editions of the IAAF Competition Rules, of 2010-2011 and of 2012-2013, in force before the 2015 IAAF ADR became applicable, contained anti-doping rules identical to those set by the 2009 IAAF ADR. Therefore, for ease of reference, any mention to the 2009 IAAF ADR shall be intended to cover also those editions which followed them, pre-dating the 2015 IAAF ADR.

carefully planned blood doping in connection with her preparation for major international competitions in at least 4 consecutive years, and deprived clean competitors of the opportunity to earn medals at World and European Championships and Olympic Games. In support of this conclusion, the Appellant refers chiefly to the expert opinions in the Initial Review, in the Joint Expert Report and in the Further Expert Report, in which Professors Schumacher, d'Onofrio and Audran answered the questions asked by IAAF as follows:

Joint Expert Report

1. Do you agree with the conclusions of the RUSADA Disciplinary Commission that samples 1, 2, 7 and 8 of the athlete's profile are abnormal as evidence of blood doping?

Yes, we agree with the conclusions of the RUSADA Disciplinary Commission that these samples provide evidence of blood manipulation. In particular, and in agreement with the recent RUSADA expert reviews, the most abnormal finding in samples 1, 2 and 7 is the marked and severe erythropoietic suppression, documented by the very low reticulocyte percentage and by the increased OFF score. The three values of reticulocytes (0.21, 0.15 and 0.16%) are extremely low and incompatible with any physiological state, including training, altitude and plasma volume variation. The apparently lower haemoglobin value in the first of these three samples, on the other hand, can reflect variation of the hydration state with hypervolemia, which can be related to important physiological variation or to abundant voluntary fluid intake before an expected anti-doping control. Haemoglobin concentration in sample 2, collected one day after sample 1, is increased by 1.3 g/dL (possibly due to haemoconcentration). These three samples 1, 2 and 7 were all collected at the time of the most important competition of the year and reproduce the typical constellation which is described in athletes who had injected erythropoiesis stimulating agents (ESA) in the preceding weeks, stopping the intake one or two weeks before the expected anti-doping control. Sample 8, on the other hand, is abnormal because of the marked increase in reticulocyte percentage with a relatively high haemoglobin value. Such pattern cannot be attributed to any physiological phenomenon (including altitude adaptation), but necessarily reflects an exogenous erythropoietic stimulation.

2. Are there samples in the athlete's profile that in your opinion are abnormal (or that form part of an abnormal sequence indicative of blood doping) in addition to those concluded by the RUSADA Commission? If so, which?

In our opinion samples 3, 5, and 10 are also abnormal. The results of samples 3 and 5 are very similar to those measured in sample 2: They were obtained at the time of important races, show even lower reticulocyte percentages (0.14% and 0.12%) and the same increase of the OFF score above 120. Such constellations repeat the typical, pathognomonic picture of an athlete who has recently discontinued an erythropoietic stimulant to avoid direct detection at the time of a sports event. Sample 10, on the other hand, mirrors the pattern visible in sample 8, with increased reticulocytes, typical of the active stimulation phase of ESA doping, usually found far from competition. Such abnormalities (consecutive phases of erythropoietic stimulation and inhibition) were mentioned in our initial reviews We highlight however that the absence of an explicit

mention of a specific sample as abnormal at the time of the initial review does not mean that that sample is implicitly normal in the context of the passport: The identification of passport abnormalities, in fact, is the result of a global analysis of the complete sequence of results.

3. In your opinion, is this the profile of an athlete who has been engaged in repeated blood doping in the period from August 2009 to August 2012?

The abuse of ESA, such as Erythropoietin by athletes typically consists of two phases: First, a stimulation phase, in which the substance is utilised and the bone marrow is stimulated to produce more red blood cells. During this phase, reticulocytes (young red blood cells) are elevated and haemoglobin concentration is usually still normal. Secondly, after a sufficient amount of additional red blood cells has been produced (haemoglobin has increased), the athlete typically stops the administration of the substance, which, due to the elevated red cell mass, leads to suppression of his red cell production, thus very low reticulocytes. This second phase is usually initiated closer to competition in order to avoid detection of the abused substance by conventional tests (1).

In the present profile, the following phases can be identified:

- *Suppression phases in sample 1 and 2 (August 2009), sample 3 (July 2010), sample 7 (August 2011).*
- *Stimulation phase in samples 8 (October 2011) and 10 (April 2012).*

Given that the stimulation phases preceding the suppression usually occur several weeks before competition, these are often not caught on tests. Until August 2011, the athlete was mostly tested prior to major events, thus suppression phases are visible throughout her profile. Also, suppression phases last for about two weeks. Given the time lag between the different tests showing a suppression pattern (several months), this implies repetitive use of blood manipulation. Stimulation phases, on the other hand, are seen in samples 8 and 10, collected far from important competitions. In summary and based on the available data, it can safely be stated that the athlete underwent at least five blood doping/ ESA cycles, identifiable through erythropoietic suppression in August 2009, July 2010 and May 2011, and periods of stimulation in October 2011 and April 2012.

4. Is the athlete's profile in Appendix 5 for the preceding period 07.08.06 – 19.08.08 indicative of blood doping? Is the athlete's profile for this period consistent with the profile you considered for the purposes of the ABP review process?

The data provided in Appendix 5 consist of 7 additional samples obtained during the years 2006, 2007 and 2008. Six of them, collected pre-competition, display high values of haemoglobin with more or less increased OFF scores, in line with what is described in the answer to the previous question. The type of abnormality observed on 19.08.2008, before the Olympic Games race, is very similar to the one described in samples 2, 3, 5 and 7 of the ABP profile. The only test with apparently normal results was carried out in December 2006, probably during a period far from competitions, where the athlete was not manipulating. The pattern therefore repeats the manipulation scenario outlined above. This is fully consistent with the doping technique visible in the ABP profile of the athlete”;

Further Expert Report

“In our previous answer to your requests, dated 18.3.2015, we stated that sample 10 (April 2012) was characterized by an increased reticulocyte percentage, typical of the active stimulation phase of doping with erythropoietic stimulating substances (ESA), like recombinant human erythropoietin (EPO). We also mentioned that sample 10 was similar in this respect to sample 8, collected in October 2012. We also described that this athlete’s profile was characterized by consecutive phases of erythropoietic stimulation and inhibition, thus consecutive doping cycles.

ESA are ergogenic doping substances, which improve work capacity and resistance to fatigue mainly by increasing red blood cell production and thereby total haemoglobin mass. The use of ESA out of competition when preparing for races is a known, well-established practice. On such basis, it is our opinion that the erythropoietic stimulation in April 2012 (sample 10) was an effective mean to increase the haemoglobin mass of the athlete (1,2). This condition highly likely improved the athlete’s preparation for the competition in May 2012 by different means:

The administration of ESA will quite rapidly induce an increase of total haemoglobin mass. This increase is associated with a swift improvement of VO_2max , one of the main descriptors of aerobic capacity and endurance performance (3–5). Thus, the athlete was, already during the ESA administration phase, able to train with an increasingly higher aerobic capacity, which is undoubtedly useful during the intensive training leading-up to an important competition. By increasing her training capacity, the performance of the athlete will subsequently benefit independent of the direct effect of the drug itself. The increased reticulocyte count in sample 10 indicates that an ESA injection had recently been performed. Increased reticulocytes counts have been documented during ESA treatment (6) and are indicative of an increasing red cell mass, which highlights the fact that already at the time of sample 10, the athlete very likely benefitted from her doping.

Once increased, an artificially boosted haemoglobin mass will remain elevated for some time. The increase in haemoglobin mass and the related improvement of VO_2max has been demonstrated to persist during at least three or four weeks after the last EPO injection (1,7,8), indicating that the oxygen transport capacity by red cells remains elevated for longer periods (9). Thus, the increased red cell mass observed in May 2012 is undoubtedly the result of the erythropoietic stimulation documented in April.

In summary, it is thus highly likely that the blood manipulation by the athlete has both assisted her training for and her performances during the competition in which she participated in May 2012”;

- iii. in cases of serious, aggravated doping violations, IAAF has always sought to punish the athletes concerned to the maximum possible extent to reflect their serious offences, including the disqualification of results, and no “fairness exception” was applied. In the Appellant’s opinion, to do otherwise in the case of the Athlete would mean to act inconsistently and to send a dangerous message to the athletics community. In that respect, IAAF makes reference to the cases of:
- Kelli White, who in 2004 admitted to the repeated use of a number of performance enhancing substances and doping methods, and accepted a 2 year ineligibility sanction starting on 17 May 2004. In addition to her ineligibility, all of her competitive results from 15 December 2000 onwards were disqualified and she

forfeited her World Championship titles in 2003;

- Marion Jones, who in 2007 admitted having regularly used steroids from September 2000 through to July 2001 (including at the 2000 Sydney Olympic Games), and accepted a 2 year sanction starting on 8 October 2007. In addition to her ineligibility, all of her competitive results from 1 September 2000 onwards were disqualified and she forfeited all of her World Championship titles, as well as the 5 Olympic medals that she won at the 2000 Olympic Games;
 - 7 Russian athletes, who in 2009 were found (through the use of DNA evidence) to have tampered with their out-of-competition urine samples by using substitute urines, and were each banned for a period of 2 years and 9 months starting from 3 September 2008. In addition, all of the athletes' competitive results were disqualified going back to April or May 2007, when the respective tampering of the samples had taken place;
 - 37 athletes, who, since the IAAF's introduction of the ABP program in 2009, have been found guilty of blood doping. In addition to serving their respective periods of ineligibility, all 37 athletes have, without exception, had their results disqualified as from the date of their first violation;
 - doping offenders in other sports, and namely of:
 - √ Jan Ullrich, who in 2010 was found guilty of a first anti-doping rule violation for the use of blood doping and other prohibited substances and was banned from the sport for a period of 2 years starting from 22 August 2011. As regards his career results, the Panel took the view that his involvement in Dr Fuentes' doping program in Spain had extended back as far as the spring of 2005 and it therefore disqualified all of his results from 1 May 2005 until the time of his retirement in 2007;
 - √ Lance Armstrong, who in August 2012 was banned for life from the sport of cycling for his involvement in the US Postal Service Team doping conspiracy and all of his career results from 1 August 1998 were disqualified without exception, including numerous Tour de France and other international titles;
- iv. only in cases of "re-testing" (such as the case of Ms Kotova mentioned by RUSADA in its submissions: § 84 below) did IAAF deviate from this approach.

70. The IAAF's primary case, therefore, is that this Panel is not bound to apply the test adopted in the case CAS 2010/A/2235 of 21 April 2001, invoked in the Decision, namely, that it would be unfair to disqualify the Athlete's results not likely to have been affected by the anti-doping rule violation. In the Athlete's case, and as mentioned, there are no grounds for applying the "fairness exception" in Article 40.9 of the 2015 IAAF ADR. In the IAAF's opinion, the damage

that the Athlete has caused to the sport of athletics should outweigh any possible consideration of fairness in her favour. Accordingly, the IAAF submits that all of the Athlete's results from 15 August 2009 should be disqualified.

71. In the alternative, the IAAF submits that, if the Panel were to find that the "fairness exception" in Article 40.9 of the 2015 IAAF ADR applies, the Panel should then nevertheless still disqualify (as the CAS Panel did in the case CAS 2010/A/2235) all results obtained between the first and the last identified abnormal samples in her profile, plus a period of one month following the last abnormal sample. The IAAF contends that an athlete, who makes a conscious decision to manipulate her blood, believes that she has escaped detection through routine controls, and repeats the illegal act should not have any of the results she achieved between those two (or more) episodes of manipulation recognised. Applying such an approach in the Athlete's case, the Panel should take into account that there is a consensus of expert opinions that the first abnormal sample in the Athlete's profile is sample 1 from 15 August 2009 and the evidence of the IAAF experts is that the last abnormal sample in the profile should be considered to be sample 10 of 13 April 2012. As a result, all of the Athlete's results between 15 August 2009 and 13 May 2012 should be disqualified. With specific reference to the 2012 Olympic Games, then, the results obtained in that occasion should also be disqualified, taking into account that, in the twelve months preceding such event, the Athlete engaged in at least two episodes of blood manipulation, as evidenced by samples (8 and 10) collected out-of-competition, clearly conducted in view of her training and preparation for the 2012 Olympic Games.
72. Finally, if the Panel were to find that the correct test is to disqualify only those of the Athlete's results, which may have been affected by her respective violations, the IAAF submits that, in addition to the results disqualified by the Anti-Doping Committee, at a minimum the Athlete's results at the 2010 European Championships, at the 2012 World Race Walking Cup and at the 2012 Olympic Games should also be disqualified, because they are likely to have been affected by her blood doping.

b. The Position of the Respondents

b.1 The Position of the First Respondent

73. In its prayers for relief, ARAF requested the CAS to rule as follows:
- i. decision of the RUSADA Committee 4/2015 dated January, 20, 2015, is upheld;*
 - ii. in any event, the ARAF shall not bear any of the costs of this arbitration;*
 - iii. the Appellant (the IAAF) and/or Ms Olga Kaniskina shall be ordered to reimburse the ARAF for the legal and other costs incurred in connection with this arbitration, in an amount to be determined at the discretion of the CAS Panel".*
74. In other words, the First Respondent asks this Panel to dismiss the appeal brought by IAAF against the Decision, which ARAF finds to be "grounded, well-founded and reasonable".

75. In support of such conclusion, ARAF submits the following:
- i. the Anti-Doping Committee took into account that:
 - the Athlete’s first abnormal blood sample was collected on 15 August 2009,
 - the disqualification of competitive results means that an athlete is considered as never having participated in that competition,
 - the Athlete was provisionally suspended from 15 October 2012, and later declared ineligible for 3 years and 2 months, so that the disqualification of all results from 15 August 2009 means that the Athlete would actually be suspended for 6 years and 4 months, when, according to the 2009 IAAF ADR, the maximum sanction was 4 years of ineligibility,
 - the “fairness” principle recognized by Article 40.9 of the 2015 IAAF ADR had to be applied in the Athlete’s case;
 - ii. all opinions expressed by the experts appointed by IAAF and RUSADA were carefully considered, and it was decided that a sample could be considered to be abnormal only when 5 of the 6 opinions described it as being abnormal, bearing in mind the seriousness of the allegations, the burden and standard of proof and the necessity to interpret in the Athlete’s favour all doubts or uncertainties;
 - iii. the Anti-Doping Committee, on such basis considered samples 1, 2, 7 and 8 to be abnormal;
 - iv. the CAS jurisprudence allows the “*selective disqualification*” of competitive results. In fact, in the case CAS 2010/A/2235, the CAS Panel disqualified only those results which had been likely affected by the anti-doping rule violation, and indicated that such a disqualification might extend no more than one month after the last abnormal sample. On this basis, the Anti-Doping Committee disqualified the Athlete’s competitive results achieved during the period commencing one month before and ending one month after the date of collection of each abnormal sample.
76. As a result, in the First Respondent’s opinion, the Decision was issued “*in strict compliance with the IAAF Anti-Doping Rules (ed. 2015), including ‘fairness’ principle, lex mitior principle, and was based on existing information, IAAF’s and RUSADA’s experts’ opinions, CAS jurisprudence*”.

b.2 *The Position of the Second Respondent*

77. In her prayers for relief, the Athlete requested the CAS to:
- “1. To reject the Appellant’s appeal;
 2. To confirm RUSADA’s decision of 20 January 2015; or
 3. In the alternative to declare that the samples 3, 5, 10, 11 and 12 are not abnormal; and to declare that no other results of the Respondent 2 than the results during the periods 15 July 2009 – 16 September 2009 and 30 July 2011 – 8 November 2011 shall be disqualified; or

4. *In the further alternative to declare that the Respondent 2's results at the 2010 European Championships on 28 July 2010, IAAF Race Walking Cup of 13 May 2012 and the 2012 Olympic Games of 11 August 2012 shall not be disqualified; and*
 5. *To order the Appellant to pay the costs that the Respondent 2 has incurred in this appeal procedure”.*
78. Preliminarily, as contended in the course of the arbitration, the Second Respondent argues that the appeal should be dismissed because CAS lacks jurisdiction to hear it. This contention, raised in a letter of 27 November 2015 and confirmed at the hearing, results from WADA’s declaration that RUSADA had to suspend all anti-doping activities under the WADC and from IAAF’s suspension of ARAF: *“this means that RUSADA [and ARAF] cannot defend the decision against which the Appellant appealed”*. In addition, according to the Second Respondent *“a suspension lift the arbitration clause as RUSADA is no longer considered by WADA as a party and does not have any rights in these proceedings. Therefore, WADA’s decision affected the arbitration clause and Respondents do not accept CAS jurisdiction anymore”*. In such connection, the Second Respondent underlined at the hearing that she had only agreed to submit to CAS disputes with ARAF and RUSADA: their absence from the proceedings affects her consent to arbitrate.
79. On the merits the Second Respondent argues that the Decision should be upheld, because:
- i. it is not proven that the Athlete violated the anti-doping rules during the 2010 European Championships, the 2012 World Race Walking Cup and the 2012 Olympic Games, and
 - ii. the principle of fairness has to be applied in this case, so that the Athlete’s results at the 2010 European Championships, the 2012 World Race Walking Cup and the 2012 Olympic Games should not be disqualified.
80. With regard to the first point (*“No violation of the anti-doping rules with respect to the European Championships, Race Walking Cup and Olympic Games”*), the Second Respondent submits:
- i. as to the burden and standard of proof, that IAAF must establish, to the *“comfortable satisfaction”* of the hearing body, that an anti-doping rule violation has occurred. In order to satisfy this burden at the required standard, *“good and clear evidence”* is to be provided. The Athlete in any case underlines that the *“comfortable satisfaction”* standard is harshly criticised, and that many authors seek the application of the stricter standard of *“beyond reasonable doubt”*;
 - ii. as to the evidence, that the ABP constitutes only an indirect method for the detection of anti-doping rule violations and that in many cases, including those mentioned by the Appellant, the anti-doping authority relied not only on the ABP evaluation, but also on other indirect and/or circumstantial evidence to conclude that an anti-doping rule violation had been committed. The Second Respondent considers that the possibility of basing a finding of an anti-doping rule violation only on the ABP is currently heavily criticized and serious doubts as to the reliability of the ABP when used alone have been raised. Relying on the ABP only would imply using an evidentiary standard so low as to be inconsistent with the right to a fair trial; in the scientific literature it is contested that

this method is scientifically sound enough; the fact that only three experts review the ABP profile is also heavily criticized; the review process lacks transparency, since the content of expert reports is not accessible to non-specialists;

- iii. that the probability for a sample to be qualified as abnormal has to amount to 99.9%: here, the probability of 99.9% regarding samples 3, 5, 10, 11 and 12 is clearly not met. The six experts tasked by IAAF and RUSADA to evaluate the Athlete's ABP could not unanimously agree on what samples are abnormal: only samples 2 and 7 were considered to be abnormal by all experts, while five experts considered sample 1 to be abnormal, three experts defined samples 3, 5 and 6 to be abnormal, two experts considered samples 4, 8 and 10 to be abnormal, and only one expert indicated as abnormal sample 9; samples 11 and 12 were not mentioned. As a result, samples 3, 5, 10, 11 and 12 are not conclusive, since the probability of 99.9% is not reached, and do not allow the conclusion that the Athlete committed an anti-doping rule violation before, during and after the 2010 European Championships, the 2012 World Race Walking Cup and the 2012 Olympic Games.

81. With regard to the second point (*"Fairness"*), the Second Respondent contends:

- i. in general terms, that the concept of fairness, *"nowhere defined"*, is however *"broad"*, as stated in case CAS 2013/A/3274. It is not an *"exception"*, but a *"general principle"*, which requires that all elements of a case be taken into account, even when not specifically mentioned. As a result, a measure can be considered to be unfair, from a substantive point of view, when it is disproportionate; in the same way, it would be unfair to disqualify results not affected by an anti-doping rule violation;
- ii. as to Article 40.9 of the 2015 IAAF ADR, that the fairness principle had to be introduced in this provision because, an athlete could otherwise be sanctioned automatically for one anti-doping rule violation in three ways: automatic disqualification from the competition in question, period of ineligibility and automatic retroactive disqualification of any results past the collection of the first positive sample. By adding the principle of fairness, an automatic retroactive disqualification can be avoided: it is only fair for everyone if an athlete is disqualified from the competition during which she was under the influence of a prohibited substance or method. However, it would be unfair to the athlete concerned that the automatic and retroactive disqualification apply in any circumstances. In addition, Article 40.1, second paragraph of the 2015 IAAF ADR also allows the results not to be disqualified under certain circumstances, in particular when the results were not influenced by the anti-doping rule violation. Furthermore, it might be unfair to base disqualifications on indirect methods/evidence such as the ABP only. In the case CAS 2010/A/2235, the CAS Panel explained well the problem of using the ABP as the only evidence for the use of prohibited methods or substances: *"Although the provisions as to disqualification are expressly made applicable to violations consisting of use of prohibited method, they are not easy to apply where the proof of such violation is to be found by reference to the ABP. The provisions are geared to the situation where the violation is an occurrence rather than a process, most obviously where the violation is the presence of a prohibited substance"*. In summary, Article 40.9 of the 2015 IAAF ADR was modified precisely to mitigate this difficulty and take into account the principle

of proportionality and to respect the athlete's personality. As a result, *"the principle of fairness shall not be considered as an exception but as a condition: if fairness does require otherwise, Rule 40.9 of the IAAF Anti-Doping Rules 2015 shall not apply"*;

- iii. as to the burden of proof in this respect, that, contrary to the Appellant's position in its appeal brief, the Second Respondent does not bear the burden of proof under Article 40.9 of the 2015 IAAF ADR. Rather, the anti-doping organization that accuses the athlete of doping must prove to the comfortable satisfaction of the Panel that fairness *"does not require otherwise"*, i.e. that all competitive results obtained by the athlete from the date of the anti-doping rule violation, through the commencement of the ineligibility period have to be disqualified;
- iv. as to the application of the principle of fairness, that:
 - the Decision is solely based on the ABP evidence, i.e. only on indirect evidence, not considered by all experts as a reliable mean to clearly establish an anti-doping violation. Moreover, the expert reports in which the ABP of the Athlete was analysed are not conclusive as to what specific sample is abnormal and as to whether the Athlete was under the influence of a doping method during the 2010 European Championships, the 2012 World Race Walking Cup and the 2012 Olympic Games. The six experts do not all agree regarding what sample should be qualified as abnormal. It is unfair to punish the Second Respondent with an additional sanction if it is not proven that she was under the influence of a prohibited substance or prohibited method during the competition;
 - it cannot be forgotten that the Second Respondent was never before found guilty of an anti-doping rule violation and thus that this case is the Second Respondent's first offence;
 - the Appellant is *"trying to dramatize"* the case *"by falsely accusing"* the Athlete of prior violations from 2006 onwards. However, the Second Respondent never committed such violations and the Appellant cannot prove these violations (especially because the WADA Athlete Blood Profile Operating Guidelines came into force only on 1 December 2009, so that no anti-doping violation can be, even indirectly, proven prior to this date);
 - the Second Respondent has already been punished with severe sanctions having an important impact on her life and career: to impose additional disqualifications is clearly disproportionate and thus unfair;
 - the samples were collected between 2009 and 2012 and the competitions at stake took place in 2010 and 2012. Thus, the proceedings have been ongoing for more than six years. The Second Respondent is not responsible for this delay and it would be unfair to sanction her with additional disqualification so late.

b.3 The Position of the Third Respondent

82. In its prayers for relief, the RUSADA requested that the CAS rule as follows:

- i. *decision of the RUSADA Commission is upheld;*
- ii. *alternatively if the CAS Panel decides that samples 3, 5 and 10 are abnormal Ms Kaniskina's results on 27 July 2010, 22 May 2011 and 13 April 2012 plus an additional period of one month are disqualified;*
- iii. *if the decision of the RUSADA Commission is upheld, IAAF reimburses RUSADA all the costs;*
- iv. *alternatively ARAF and Ms Olga Kaniskina shall bear all the costs".*

83. According to RUSADA, the disputed questions in this arbitration are:

- i. *"who shall prove the principle of "fairness" (the athlete or the RUSADA commission on its own)", and*
- ii. *"if there were exceptional circumstances that required application of "fairness" principle in this case".*

84. Concerning the first point, RUSADA underlines that Article 40.9 of the 2015 IAAF ADR provides no indications as to who bears the burden of proving the applicability of the "fairness principle" in any given case. However, RUSADA refers to the correspondence sent by IAAF in another case (the case of Ms Kotova), in which IAAF would have agreed that the "fairness principle" can be applied at the discretion of the hearing body, without any burden for the athlete to invoke or prove it.

85. Concerning the second point, RUSADA emphasizes that:

- i. *"taking into consideration that the Athlete was provisionally suspended from 15 October 2012 and later declared ineligible for three years and two months, disqualification of all results from 15 August 2009 [date of collection of the first abnormal blood sample] means that the Athlete would be actually suspended for six years and four months", a period "significantly longer" than the maximum sanction contemplated by the 2009 IAAF ADR (four years);*
- ii. the selective disqualification of results decided by the Anti-Doping Committee is fair both for the Athlete and the clean athletes who competed against her, since the results that were achieved by unfair means have been disqualified, while those results that were not affected by the use of prohibited substances or methods have been left untouched;
- iii. it is not possible to use the data of samples collected in 2006-2009 to claim that the Athlete engaged in a doping scheme over a long period, even before the first sample was entered into her ABP, since:
 - the data from samples collected before 1 December 2009 (when the ABP program became applicable) cannot be used to bring charges and cannot be taken into account due to their questionable scientific reliability, as they were analysed under other laboratory reporting requirements;
 - IAAF did not bring any charge against the Athlete based on those data, and waited for additional tests over several years without proceeding;
 - all the experts involved in the review of the Athlete's blood values specified the samples and the periods affected by the use of prohibited substances or methods –

- which means that other samples and periods were within the physiological limits;
- iv. the decision of the Anti-Doping Committee, not to consider samples 3, 5 and 10 as abnormal, because only those samples so declared by at least five of the six experts involved were considered to be abnormal, was in line with the applicable standard of evidence imposed on the anti-doping organization to establish an anti-doping rule violation, and took into account the severity of the consequences that would have derived for the Athlete, including disqualification of results at major sporting events.

3. LEGAL ANALYSIS

3.1 Jurisdiction

86. CAS has jurisdiction according to Article R47 of the Code, under which:

“an appeal against the decision of a federation, association or sports-related body may be filed with the CAS insofar as the statutes or regulations of the said body so provide or as the parties have concluded a specific arbitration agreement ...”.

87. More specifically, the jurisdiction of CAS is based on Article 42 of the 2015 IAAF ADR, in force at the time the Decision was rendered and the appeal to CAS was filed, which reads, in the pertinent parts, as follows:

Article 42 – “Appeals”

Decisions subject to Appeal

1. *Unless specifically stated otherwise, all decisions made under these Anti-Doping Rules may be appealed in accordance with the provisions set out below. All such decisions shall remain in effect while under appeal unless the appellate body orders otherwise or unless otherwise determined in accordance with these Rules Before an appeal is commenced, any post-decision review provided in these Anti-Doping Rules must be exhausted*
 - (a) *Scope of Review Not Limited: the scope of review on appeal includes all issues relevant to the matter and is expressly not limited to the issues or scope of review before the initial decision maker.*
 - (b) *CAS Shall Not Defer To The Findings Being Appealed: in making its decision, CAS need not give deference to the discretion exercised by the body whose decision is being appealed.*

Appeals from Decisions regarding Anti-Doping Rule Violations or Consequences

2. *The following is a non-exhaustive list of decisions regarding anti-doping rule violations and Consequences that may be appealed under these Rules: ... a decision imposing Consequences or not imposing*

Consequences for an anti-doping rule violation; ... a decision failing to impose Consequences for an anti-doping rule violation in accordance with these Rules;

Appeals arising from International Competitions or Involving International-Level Athletes

3. *In cases arising from an International Competition or involving International-Level Athletes or their Athlete Support Personnel, the first instance decision of the relevant body of the Member shall not be subject to further review at national level and shall be appealed exclusively to CAS in accordance with the provisions set out below.*

Parties Entitled to Appeal

5. *In any case arising out of an International Competition or involving an International-Level Athlete or his Athlete Support Personnel, the following parties shall have the right to appeal to CAS:*
 - (c) *the IAAF;*

Time Limits for Filing Appeals to CAS

15. *Unless stated otherwise in these Rules ..., the appellant shall have forty-five (45) days in which to file his statement of appeal with CAS, such period starting from the day after the date of receipt of the decision to be appealed (or where the IAAF is the prospective appellant, from the day after the date of receipt of both the decision to be appealed and the complete file relating to the decision, in English or French) Within fifteen days of the deadline for filing the statement of appeal, the appellant shall file his appeal brief with CAS and, within thirty days of receipt of the appeal brief, the respondent shall file his answer with CAS.*

Respondents to the CAS Appeal

18. *As a general rule, the respondent to a CAS appeal shall be the party which has taken the decision that is subject to appeal. Where the Member has delegated the conduct of a hearing under these Rules to another body, committee or tribunal ..., the respondent to the CAS appeal against such decision shall be the Member.*
19. *Where the IAAF is appellant before CAS, it shall be entitled to join as additional respondent(s) to the appeal such other parties as it deems to be appropriate, including the Athlete, Athlete Support Personnel or other Person or entity that may be affected by the decision.*

The CAS Appeal

22. *All appeals before CAS shall take the form of a re-hearing and the CAS Panel shall be able to substitute its decision for the decision of the relevant tribunal of the Member or the IAAF where it considers the decision of the relevant tribunal of the Member or the IAAF to be erroneous or procedurally unsound. The CAS Panel may in any case add to or increase the Consequences that were imposed in the contested decision.*
23. *In all CAS appeals involving the IAAF, CAS and the CAS Panel shall be bound by the IAAF*

Constitution, Rules and Regulations (including the Anti-Doping Regulations). In the case of any conflict between the CAS rules currently in force and the IAAF Constitution, Rules and Regulations, the IAAF Constitution, Rules and Regulations shall take precedence.

24. *In all CAS appeals involving the IAAF, the governing law shall be Monegasque law and the arbitrations shall be conducted in English, unless the parties agree otherwise.*
 25. *The CAS Panel may in appropriate cases award a party its costs, or a contribution to its costs, incurred in the CAS appeal.*
 26. *The decision of CAS shall be final and binding on all parties, and on all Members, and no right of appeal will lie from the CAS decision. The CAS decision shall have immediate effect and all Members shall take all necessary action to ensure that it is effective”.*
88. The First Respondent and the Third Respondent expressly accepted CAS jurisdiction, by signing the Order of Procedure. On the other hand, the Second Respondent, who had not raised any objection in this respect and had filed her submissions on the merits of the dispute, challenged CAS jurisdiction during the proceedings, when (i) RUSADA announced that it had been suspended by WADA and that it had to stay any anti-doping related activity, and (ii) IAAF suspended ARAF’s status of member federation. More specifically, the Second Respondent invoked the suspension of RUSADA and ARAF to deny CAS jurisdiction because (i) RUSADA and ARAF could not defend the Decision; and (ii) the Second Respondent only agreed to submit to CAS disputes with ARAF and RUSADA, meaning that their absence from the proceedings would affect her consent to arbitrate.
 89. IAAF defined such objection as “*parasitic*”, “*vexatious*”, “*opportunistic*”, corresponding to an “*inappropriate procedural conduct*”. In the Panel’s opinion, this objection is frivolous and must be rejected.
 90. First, the Second Respondent grounded her objection on the impossibility for RUSADA and ARAF to take part in the arbitration and defend the Decision. However, RUSADA and ARAF did take part in the arbitration in defence of the Decision: their position as parties was not under any point of view affected by WADA’s and IAAF’s suspension; no issue was raised as to their ongoing existence as legal entities, with full capacity to act in arbitration proceedings; WADA and IAAF confirmed they could appear as respondents; RUSADA and ARAF accepted CAS jurisdiction and did not raise the objection voiced by the Athlete.
 91. Second, the Second Respondent contended that she only agreed to submit to arbitration disputes with ARAF and RUSADA, meaning that their absence from the proceedings would affect her consent to arbitrate. However, as mentioned, RUSADA and ARAF participated in the arbitration without objecting to CAS jurisdiction. In any case, the Second Respondent’s contention does not correspond to the provisions in the IAAF ADR defining CAS jurisdiction over this arbitration. Under those rules, and specifically pursuant to Article 42.19 of the 2015 IAAF ADR, the Athlete agreed to arbitrate disputes with IAAF, and not with RUSADA and/or ARAF: ARAF was named as a respondent by IAAF in accordance with Article 42.18 of the

2015 IAAF ADR, and RUSADA is not a necessary party in such arbitration.

92. As a result, the Second Respondent's objection must be rejected because it is devoid of any merits.

3.2 Appeal Proceedings

93. As these proceedings involve an appeal against a decision rendered by RUSADA, brought on the basis of provisions contained in the statutes of an international federation, they are considered and treated as appeal arbitration proceedings in a disciplinary case heard by a national anti-doping organization, within the meaning and for purposes of the Code.

3.3 Admissibility

94. The statement of appeal was filed within the deadline set in Article 42.15 of the 2015 IAAF ADR, counted from the day of receipt by IAAF of the Decision. Accordingly, the appeal is admissible.

3.4 Scope of the Panel's Review

95. According to Article R57 of the Code,

“the Panel shall have full power to review the facts and the law. It may issue a new decision which replaces the decision challenged or annul the decision and refer the case back to the previous instance. ...”.

96. Article 42.15 of the 2015 IAAF ADR confirms in that regard that:

“All appeals before CAS shall take the form of a re-hearing and the CAS Panel shall be able to substitute its decision for the decision of the relevant tribunal of the Member or the IAAF where it considers the decision of the relevant tribunal of the Member or the IAAF to be erroneous or procedurally unsound. The CAS Panel may in any case add to or increase the Consequences that were imposed in the contested decision”.

3.5 Applicable Law

97. The law applicable in the present arbitration is identified by the Panel in accordance with Article R58 of the Code.

98. Pursuant to Article R58 of the Code, the Panel is required to decide the dispute

“... according to the applicable regulations and, subsidiarily, to the rules of law chosen by the parties or, in the absence of such a choice, according to the law of the country in which the federation, association or sports-related body which has issued the challenged decision is domiciled or according to the rules of law, the application of which the Panel deems appropriate. In the latter case, the Panel shall give reasons for its decision”.

99. Pursuant to Article 42.23 of the 2015 IAAF ADR (and to Article 42.22 of the 2009 IAAF ADR):

“In all CAS appeals involving the IAAF, CAS and the CAS Panel shall be bound by the IAAF Constitution, Rules and Regulations (including the Anti-Doping Regulations). In the case of any conflict between the CAS rules currently in force and the IAAF Constitution, Rules and Regulations, the IAAF Constitution, Rules and Regulations shall take precedence”.

100. In accordance, then, with Article 42.23 of the 2015 IAAF ADR (and to Article 42.22 of the 2009 IAAF ADR):

“In all CAS appeals involving the IAAF, the governing law shall be Monegasque law”.

101. As a result, pursuant to Article R58 of the Code, this Panel will apply primarily the IAAF rules and regulations, and subsidiarily Monegasque law.

102. The IAAF provisions set by the IAAF ADR which are relevant in this arbitration include the following:

i. from the 2009 IAAF ADR:

Article 40.9 – *“Disqualification of Results in Competitions Subsequent to Sample Collection or Commission of an Anti-Doping Rule Violation”*

“In addition to the automatic disqualification of the results in the Competition which produced the positive sample under Rules 39 and 40, all other competitive results obtained from the date the positive Sample was collected (whether In-Competition or Out-of-Competition) or other anti-doping rule violation occurred through to the commencement of any Provisional Suspension or Ineligibility period shall be Disqualified with all of the resulting Consequences for the Athlete including the forfeiture of any titles, awards, medals, points and prize and appearance money”;

ii. from the 2015 IAAF ADR:

Article 40.9 – *“Disqualification of Individual Results in Competitions Subsequent to Sample Collection or Commission of an Anti-Doping Rule Violation”*

“In addition to the automatic Disqualification of the Athlete’s individual results in the Competition which produced the positive sample under Rules 39 and 40, all other competitive results obtained by the Athlete from the date the positive Sample was Collected (whether In-Competition or Out-of-Competition) or other anti-doping rule violation occurred, through to the commencement of any Provisional Suspension or Ineligibility period shall, unless fairness requires otherwise, be Disqualified with all of the resulting Consequences for the Athlete including the forfeiture of any titles, awards, medals, points and prize and appearance money”.

3.6 The Dispute

103. The object of the dispute, as already underlined, is the portion of the Decision (point 3) which, *“pursuant to the Art. 40.9”* of the 2015 IAAF ADR *“and taking into account fairness and proportionality”*,

disqualified the competitive results of the Athlete in two different periods (15 July 2009 – 15 September 2009 and 30 July 2011 – 8 November 2011), corresponding to periods starting one month before and ending one month after the date of collection of those samples entered into the Athlete’s ABP that the Anti-Doping Committee conclusively found to be abnormal, *i.e.* sample 1 of 15 August 2009, sample 2 of 16 August 2009, sample 7 of 30 August 2011 and sample 8 of 8 October 2011. IAAF challenges this “selective” disqualification of results, submitting, in its primary claim, that all results achieved by the Athlete from the date of her first abnormal sample (15 August 2009) to the date she accepted a provisional suspension (15 October 2012) must be disqualified, including those obtained in the 20Km walk competition on 28 July 2010 at the 2010 European Championships (where the Athlete won the gold medal and became the European champion), on 1 May 2012 at the 2012 World Race Walking Cup (where she won the silver medal) and on 11 August 2012 at the 2012 Olympic Games (where the Athlete won the silver medal).

104. The other portions of the Decision, whereby the Athlete was found guilty of an anti-doping rule violation on the basis of the 2009 IAAF ADR (point 1) and was declared ineligible for a period of 3 years and 2 months (point 2), remain unchallenged, and are therefore final.
105. As a result, the main issue that this Panel has to decide is whether the Decision was correct in disqualifying only some of the results achieved by the Athlete in the period following the date on which the anti-doping rule violation was found to have been committed and the beginning of the period of (provisional) suspension/ineligibility. In this connection, the parties brought some other incidental issues to the attention of the Panel during the course of the arbitration: *inter alia*, the identification of the rules which have to be applied, and, if relevant, the meaning and conditions of application of the “fairness exception” mentioned at Article 40.9 of the 2015 IAAF ADR.
106. In this context, the Second Respondent took issue with the use of the ABP as a method for identifying anti-doping rule violations. Contrary to the Appellant’s objections, the Panel considers that this issue is relevant even though this arbitration concerns only the disqualification of results and not the unchallenged and therefore final finding of an anti-doping rule violation, which was based on the abnormal profile shown by the Athlete’s ABP. Indeed, consistent with the Decision’s approach, which the Second Respondent defends and wishes to be confirmed, the criticism as to the reliability of the ABP can be understood as aiming to show that insufficient evidence has been submitted to prove that some of the samples included in the ABP of the Athlete are abnormal, and therefore to allow the conclusion, from the Athlete’s perspective, that they should not be taken into account when determining whether the results achieved in the period surrounding those disputed samples have to be disqualified. In the same way, the Second Respondent appears to invoke the alleged unreliability of the ABP method as a factor to be taken into account when assessing, in general terms, the “fairness” of the disqualification (or of the non-disqualification) of results. In such regard (but only within those limits), the Athlete’s submissions are admissible and relevant: on the other hand, they would not be (and indeed are not) admissible to the extent they were (or are) intended to dispute the foundation of those points of the Decision which are final. By not challenging (and indeed by defending) the Decision, the Athlete accepts the conclusion that her ABP gave sufficient

evidence, at least with respect to some of the samples, to ground the conclusion that she committed an anti-doping rule violation.

107. At the same time, but conversely, the Panel notes that no other procedural issues remain to be addressed, except for confirming and explaining some directions issued in the course of the proceedings. The Second Respondent, who quite strongly criticized the Panel, for instance, with respect to the hearing of the expert witnesses, in the end waived her objections, recognizing (at least in this regard) that her right to be heard and to be treated equally had been respected.
108. The Panel, therefore, can turn to the examination of the main issue that has to be decided: was the Decision correct in the portion in which it disqualified only some, and not all, of the results achieved by the Athlete after the date of commission of the anti-doping rule violation for which she was found guilty?
109. As said, in order to answer such question, the Panel was requested to identify, first, the rules which apply for a decision on the disqualification of the Athlete's results. The IAAF ADR have evolved over the years: at the time the anti-doping rule violation was committed (*i.e.*, in the period covered by the Athlete's ABP: August 2009 – August 2012), the 2009 IAAF ADR were in force¹¹; when the Decision was adopted (on 20 January 2015), the 2015 IAAF ADR had become applicable.
110. Taking into account such evolution, and as already underlined, the Anti-Doping Committee decided to apply (i) the 2009 IAAF ADR, defined to be the "Old Rules", to the issue of liability (finding of an anti-doping rule violation) and to the determination of one of the consequences of the established liability (ineligibility period), and (ii) the 2015 IAAF ADR, defined to be the "New Rules", to another consequence of the same finding (disqualification of results). Such peculiar conclusion was reached by invoking the "*tempus regit actum*" principle to justify the application of the 2009 IAAF ADR, and the "*lex mitior*" principle to explain the application of the 2015 IAAF ADR. Article 40.9 of the latter, while providing for the disqualification of results (in the same way as Article 40.9 of the 2009 IAAF ADR), allows, unlike the former, the non-disqualification for reasons of "fairness". The most recent version of the IAAF ADR was thus considered to be more favourable to the Athlete, and was consequently applied as "*lex mitior*". The Anti-Doping Committee therefore found *ex officio* the existence of reasons of "fairness" to disqualify only some of the Athlete's results; with the consequence that the results achieved by the Athlete at the 2011 World Championships and at the 2012 Olympic Games were left untouched.
111. The Appellant disputes this approach. Even though it had accepted in its written submissions that the issue of the disqualification of the Athlete's results should be governed by the 2015 IAAF ADR, the Appellant took issue on this point, at the hearing, clarifying that precedents of the European Court of Human Rights and of the Swiss Federal Tribunal indicate that the "*lex mitior*" principle was improperly applied. The Appellant argued that the hearing body cannot

¹¹ See the preceding footnote 10: the reference to the 2009 IAAF ADR is intended to cover also those editions of the IAAF ADR which followed them and preceded the 2015 IAAF ADR.

undertake a rule-by-rule comparison of the two systems (the 2009 IAAF ADR and the 2015 IAAF ADR), picking the most favourable rule of each system, because it would thereby create a new *ad hoc* disciplinary regime composed of a miscellany of rules deriving from different systems. The Appellant added that the Anti-Doping Committee should have, and the CAS now must, apply whichever of the 2009 or the 2015 system is most favourable for the accused, without picking individual provisions from each. The Decision is wrong because it mixed provisions from both the 2009 and 2015 system. Rather, the Anti-Doping Committee should have applied the rules in force at the time of the anti-doping rule violation (*i.e.*, the 2009 IAAF ADR), which were more favourable to the Athlete, since they provided a standard sanction for her infringement of 2 years of ineligibility, even though they did not contain the “fairness exception”.

112. The Respondents did not raise any objection to the admissibility of the Appellant’s submission of this new line of reasoning, simply insisting that the “fairness exception” should apply also in the context of the 2009 IAAF ADR, because it is a general principle enshrined also in that edition of the IAAF ADR, and expressed in the WADC.
113. The Panel notes that it is undisputed that the 2009 IAAF ADR govern the issue of the commission by the Athlete of an anti-doping rule violation and were applied to the determination of the corresponding ineligibility period. This point was finally settled by the Decision, which was not challenged in this respect. It is therefore accepted that the 2009 IAAF ADR (and not the 2015 IAAF ADR) provide the overall legal framework to judge on the Athlete’s anti-doping rule violation and its consequences.
114. On such basis, the application of the 2009 IAAF ADR would in principle also imply the applicability of Article 40.9 of the 2009 IAAF ADR, which does not provide for a “fairness exception”. However, the question before the Panel is whether the “fairness exception” (within the meaning to be further specified) is also to be read into the 2009 IAAF ADR, as a general principle, or by reference to Article 40.9 of the 2015 IAAF ADR, pursuant to the “*lex mitior*” principle.
115. The Panel sees the force of the IAAF argument that specific rules cannot be picked from different systems. The *lex mitior* principle prevents the continued applicability of a disciplinary rule after it has been replaced by a more lenient one, and reflects, in favour of the accused, the evolution of a legislative policy, which translates into rules the opinion that the same infringement is less severe than it was previously perceived. However, this principle cannot be applied in a way that creates a law that never existed, composed of a mixture of old and new rules and upsetting the rationale of both systems.
116. At the same time the Panel, even though it remains unpersuaded, cannot exclude as *prima facie* misplaced the Respondents’ arguments regarding the possibility of applying a general principle of “fairness” in deciding whether some results are to be left untouched, even in the absence of an explicit rule to this effect in the 2009 IAAF ADR.
117. However, the Panel does not find it necessary to draw a final conclusion on the issue of whether

the 2009 IAAF ADR should be read as including a “fairness exception”. As indicated below, even assuming it does, the Panel would reach the same conclusion that it should not apply here, because the Panel cannot see any factors justifying a deviation from the rule of automatic disqualification set by Article 40.9 of the 2009 IAAF ADR and of the 2015 IAAF ADR.

118. In both versions, the finding of an anti-doping rule violation triggers the disqualification (i) of the results achieved in the competition which produced a positive sample, and (ii) of all other competitive results obtained in the period between (a) the date of the positive sample’s collection, or of the other anti-doping rule violation, and (b) the date of commencement of the ineligibility (or provisional suspension). The version of Article 40.9 of the 2015 IAAF ADR makes clear that, while the disqualification of the results achieved at the competition which produced the positive sample is automatic and unavoidable, the disqualification of the competitive results obtained in the subsequent period applies “*unless fairness requires otherwise*”, *i.e.* unless it is fair not to disqualify them. In other words, “fairness” should be found in order not to disqualify the results. It is therefore an exception to the general disqualification rule. In light of the provision’s clear wording, the Panel therefore disagrees with the Respondents’ submissions that “fairness” is a precondition to the disqualification of a result.
119. The findings (undisputed in this arbitration, and indeed never contested also before the Anti-Doping Committee) that the Second Respondent is responsible for an anti-doping rule violation (identified through the examination of her ABP) and that her anti-doping rule violation can be set (as mentioned in the Decision) at the date of the collection of sample 1 in her ABP (and therefore on 15 August 2009) thus mean that her competitive results obtained in the period between 15 August 2009 and 15 October 2010 (date on which she accepted the provisional suspension) must be disqualified, unless fairness requires otherwise.
120. The Panel finds that no reasons of fairness exist in this case that could justify mitigating the effects of Article 40.9 of the 2009 IAAF ADR. This conclusion applies irrespective of the discussion between the parties as to whether the anti-doping organization or the athlete bears the burden of proving whether it is fair to disqualify the results in question.
121. As a preliminary matter, the Panel notes that “fairness” is a broad concept (CAS 2013/A/3274, para. 85), covering a number of elements that the deciding body can take into account in its decision not to disqualify some results. The CAS precedents (in general terms, *inter alia*, CAS 2007/A/1283, para. 53; CAS 2013/A/3274, para. 85-88) took into account a number of factors, such as the nature and severity of the infringement (CAS 2010/A/2083, para. 81), the length of time between the anti-doping rule violation, the result to be disqualified and the disciplinary decision, the presence of negative tests between the anti-doping rule violation and the competition at which the result to be disqualified was achieved, and the effect of the infringement on the result at stake (CAS 2008/A/1744, para. 76; CAS 2007/A/1362 & 1393, para 7.22). The Panel underlines that no single element is decisive alone: an overall evaluation of them is necessary.
122. In that regard, and bearing in mind the submissions of the parties:

- i. as to the characteristics of the anti-doping rule violation, the Panel notes that the Athlete engaged in continuous, intentional and severe violations of the anti-doping regulations. The point, indeed, is confirmed by the unchallenged findings in the Decision, leading to the setting of an ineligibility period, in a measure which is considerably longer than the minimum provided by the 2009 IAAF ADR, based on aggravating circumstances. In the same vein, the Panel is comforted by the opinion of the IAAF experts filed in the course of this arbitration¹², only marginally and “hypothetically” challenged by the Respondents’ experts. As it has been underlined, the Athlete’s ABP shows abnormalities indicating that the Athlete was engaged in blood doping cycles over four years, from 2009 to 2012. The Panel, more specifically, based on the expert opinions reviewed, remarks that the Athlete’s ABP includes a number of samples showing very low RET% values as well samples with a very high RET% count, and that samples with the highest values for HGB show a low RET% count. At the same time, the Panel notes that samples 3, 5 and 10 must be considered abnormal: samples 3 and 5 show a pattern similar to that indicated by sample 2, considered abnormal in the Decision, which shows a suppression phase; sample 10 corresponds to sample 8, found abnormal by the Anti-Doping Committee, and shows a stimulation phase in the lead up to the competitions scheduled for 2012. Such elements, together with the overall fluctuations, show several doping phases: an erythropoietic suppression in August 2009, July 2010 and May 2011; stimulation in October 2011 and April 2012¹³. In other words, the Athlete’s case is not the “unfortunate” case of an athlete, who inadvertently ingested a contaminated product, or of an athlete whose degree of fault is light, or even of a cheater on a single occasion, but of an athlete, who put in place a careful scheme to avoid detection of the prohibited substances or methods she was using, but still gain the advantage of her unlawful practice¹⁴;
- ii. as to the effects of the infringements on the results at stake, the Panel is convinced by the Appellant’s submissions, based on the expert reports, that blood doping, in the way it was conducted by the Athlete, was intended to have, and actually had, long-lasting effects, as *inter alia* it improved the Athlete’s capacity to train, for, otherwise, the Athlete’s use of a prohibited method or of a prohibited substance chiefly in pre-competition periods would be substantially devoid of purpose. Therefore, the raising of doubts by the Respondents as to the abnormality of the analytical results of some of the samples in the Athlete’s ABP does not mean that at the time those samples were collected the Athlete was not “benefiting” from the effects of blood doping evidenced by abnormal samples. It cannot therefore be maintained that some of the competitions in the period following (or

¹² The Panel remarks indeed the experience and expertise of the Appellants’ experts, and, as the most important element, the weight of published literature which supported their opinions.

¹³ The Panel in that regard understands, in fact, that (as explained by the experts heard at the hearing and underlined also in the case CAS 2010/A/2235, para 100) blood withdrawal produces lower than normal hemoglobin (HGB, measured by its weight in a given quantity of blood) and higher than normal percentage of reticulocytes in blood (RET%), since the bone marrow responds to blood loss by releasing a higher number of “young” blood cells. The reverse happens post EPO-stimulation, which produces an heritropoyetic suppression, *i.e.* an inhibition in the physiological process which produces red blood cells.

¹⁴ Note that in CAS 2013/A/3274, to which the Second Respondent refers, a negative test and the light degree of fault were decisive elements for the Sole Arbitrator not to disqualify the results: para. 89 of the award of 31 January 2014.

- comprised within) the various cycles of blood manipulation were not affected by the Athlete's doping practices;
- iii. as to the principle applied in the case CAS 2010/A/2235, the Panel remarks that the CAS Panel in that case, unlike the Anti-Doping Committee, disqualified all results in the period between the first and the last abnormal sample and considered, in applying the fairness exception, that it was unlikely that the results outside this period had been affected by the athlete's anti-doping violation. In the Athlete's case, the Panel considers that the Athlete's repeated violations of the anti-doping regulations over a long period of time make it impossible to exclude, in "fairness", some results, and chiefly the result obtained at the 2010 European Championships, at the 2012 World Race Walking Cup and at the 2012 Olympic Games, from disqualification. Indeed, the "doping cycle" in the first part of 2012 was clearly intended to enhance the sporting performance of the Athlete at the 2012 World Race Walking Cup and at the 2012 Olympic Games, the major competitions scheduled that year immediately after the mentioned "cycle";
 - iv. as to the length of time between the anti-doping rule violation, the result to be disqualified and the starting date of the ineligibility period, the Panel underlines that such factor does not justify application of the "fairness exception". Indeed, the most recent "doping cycle" evidenced by the ABP took place in the first part of 2012, only months before the major competitions of that year and the day on which the Athlete's provisional suspension commenced;
 - v. as to the absence of positive tests and the method applied to evaluate the samples provided by the Athlete to find an anti-doping rule violation, the Panel notes that the ABP profile has been validated in a long line of CAS cases (see *inter alia*: CAS 2010/A/2174; TAS 2010/A/2178; CAS 2010/A/2308 & 2335; CAS 2012/A/2773; as well as CAS 2010/A/2235) as a reliable means to detect blood doping, even in the absence of positive tests, through the identification of abnormal values calling for an explanation by the athlete in question. Even the Vorobiov Opinion, confirmed at the hearing by Professor Vorobiov himself, supports this conclusion. In addition, the Decision, unchallenged on this point, found the commission of repeated anti-doping rule violations based on the ABP evidence and the Athlete's failure to provide explanations regarding the abnormal values. In any case, the Panel is not persuaded by the literature invoked by the Second Respondent to cast doubts on the reliability of the ABP program. The Panel remarks that such literature dates back from some years ago and deals more with legal than scientific issues, and is therefore more than comfortably satisfied that the finding of an anti-doping rule violation based on the review of the Athlete's ABP does not constitute a ground not to disqualify (for reasons of "fairness") the results she obtained following her anti-doping rule violation;
 - vi. as to the principle of proportionality, the Panel finds that, contrary to the Respondents' contention, it requires the retroactive disqualification of results, rather than the opposite. The principle of proportionality implies that there must be a reasonable balance between the kind of misconduct and the sanction, and in particular that (i) the measure taken by the governing body can achieve the envisaged goal, (ii) the measure taken by the governing body is necessary to reach the envisaged goal, and (iii) the constraints on the

affected person resulting from the measure are justified by the overall interest of achieving the envisaged goal. In other words, to be proportionate, a measure must not exceed what is reasonably required in the search for a legitimate objective (CAS 2005/C/976 & 986, §§ 139-140, citing CAS precedents, legal doctrine and Swiss jurisprudence). In this respect, the Panel notes that:

- the purpose of disqualification in the Athlete's case is *inter alia* to prevent her from gaining the advantage sought by her intentional, continued and severe doping violations over other competitors, who competed without doping;
- the measure of disqualification is certainly capable of achieving the envisaged goal, since it implies the cancellation of the results obtained;
- the measure of disqualification is necessary to reach the envisaged goal, because the Athlete, who cheated in the preparation of a given competition, would otherwise keep the benefits of the results achieved to the detriment of clean competitors, and
- the constraints on the Athlete are justified by the overall interest of achieving the envisaged goal.

123. In light of the foregoing and of an overall evaluation of all relevant elements, the Panel concludes that all competitive results obtained by the Athlete from the date of first commission of the anti-doping rule violation (15 August 2009) through to the commencement of her provisional suspension (15 October 2012) must be disqualified, with all resulting consequences in accordance with Article 40.9 of the 2009 IAAF Rules. No reasons of fairness can be found not to disqualify them.

3.7 Conclusion

124. In light of the foregoing, the Panel unanimously holds that the appeal brought by IAAF is to be allowed and all competitive results obtained by the Athlete from 15 August 2009 to 15 October 2012 are disqualified, with all resulting consequences in accordance with Article 40.9 of the 2009 IAAF Rules. Point 3 of the Decision is modified accordingly.

ON THESE GROUNDS

The Court of Arbitration for Sport rules that:

1. The appeal filed on 25 March 2015 by the International Association of Athletics Federations (IAAF) against the decision issued on 20 January 2015 by the Disciplinary Anti-Doping Committee of the Russian Anti-Doping Agency is granted.
2. Point 3 of the decision issued on 20 January 2015 by the Disciplinary Anti-Doping Committee of the Russian Anti-Doping Agency is partially modified.
3. All competitive results obtained by Ms Olga Kaniskina from 15 August 2009 to 15 October 2012 are disqualified, with all resulting consequences in accordance with Article 40.9 of the 2015 IAAF Rules.

(...)

7. All other motions or prayers for relief are dismissed.